Acyltransferases and uses thereof in fatty acid production

ABSTRACT

The present invention relates to the recombinant manufacture of polyunsaturated fatty acids. Specifically, it relates to acyltransferase polypeptides, polynucleotides encoding said acyltransferases as well as vectors, host cells, non-human transgenic organisms containing said polynucleotides. Moreover, the present invention contemplates methods for the manufacture of polyunsaturated fatty acids as well as oils obtained by such methods.

RELATED APPLICATIONS

This application is a divisional application of U.S. application Ser. No. 13/806,269 filed Dec. 21, 2012, now U.S. Pat. No. 9,388,437, which is a national stage application (under 35 U.S.C. § 371) of PCT/EP2011/060315, filed Jun. 21, 2011 which claims benefit of European Application No. 10167342.4 filed Jun. 25, 2010, and U.S. Provisional Application No. 61/358,431, filed Jun. 25, 2010. The entire contents of each of these applications are hereby incorporated by reference herein in their entirety.

SUBMISSION OF SEQUENCE LISTING

The Sequence Listing associated with this application is filed in electronic format via EFS-Web and hereby incorporated by reference into the specification in its entirety. The name of the text file containing the Sequence Listing is Sequence_Listing_074021_0214_01. The size of the text file is 216 KB and the text file was created on May 19, 2016.

The present invention relates to the recombinant manufacture of polyunsaturated fatty acids. Specifically, it relates to acyltransferase polypeptides, polynucleotides encoding said acyltransferase polypeptides as well to vectors, host cells, non-human transgenic organisms containing said polynucletides. Moreover, the present invention contemplates methods for the manufacture of polyunsaturated fatty acids as well as oils obtained by such methods.

Fatty acids and triacylglycerides have a various applications in the food industry, in animal feed, supplement nutrition, and in the cosmetic and pharmacological and pharmaceutical field. The individual applications may either require free fatty acids or triacylglycerides. In both cases, however, polyunsaturated fatty acids either free or esterified are of pivotal interest for many of the aforementioned applications. In particular, polyunsaturated omega-3-fatty acids and omega-6-fatty acids are important constituents in animal and human food. These fatty acids are supposed to have beneficial effects on the overall health and, in particular, on the central nervous system, the cardivovascular system, the immune system, and the general metabolism. Within traditional food, the polyunsaturated omega-3-fatty acids are mainly found in fish and plant oils. However, in comparison with the needs of the industry and the need for a beneficial diet, this source is rather limited.

The various polyunsaturated fatty acids (PUFA) and PUFA-containing triglycerides are also mainly obtained from microorganisms such as Mortierella and Schizochytrium or from oil-producing plants such as soybean or oilseed rape, algae such as Crypthecodinium or Phaeodactylum and others, where they are usually obtained in the form of their triacylglycerides. The free PUFA are usually prepared from the triacylglycerides by hydrolysis. However, long chain polyunsaturated fatty acids (LCPUFA) having a C-18, C-20, C-22 or C-24 fatty acid body, such as docoahexaenoic acid (DHA), eicosapentaenoic acid (EPA), arachidonic acid (ARA), dihomo-gamma-linolenic acid or docosapentaenoic acid (DPA) can not be efficiently isolated from natural oil crop plants such as oilseed rape, soybean, sunflower or safflower. Conventional natural sources of these fatty acids are, thus, merely fish, such as herring, salmon, sardine, redfish, eel, carp, trout, halibut, mackerel, zander or tuna, or from algae.

Especially suitable microorganisms for the production of PUFA in industrial scale are microalgae such as Phaeodactylum tricornutum, Porphoridium species, Thraustochytrium species, Nannochloropsis species, Schizochytrium species or Crypthecodinium species, ciliates such as Stylonychia or Colpidium, fungi such as Mortierella, Entomophthora or Mucor and/or mosses such as Physcomitrella, Ceratodon and Marchantia (Vazhappilly 1998, Botanica Marina 41: 553-558; Totani 1987, Lipids 22: 1060-1062; Akimoto 1998, Appl. Biochemistry and Biotechnology 73: 269-278). Strain selection has resulted in the development of a number of mutant strains of the microorganisms in question which produce a series of desirable compounds including PUFA. However, the mutation and selection of strains with an improved production of a particular molecule such as the polyunsaturated fatty acids is a time-consuming and difficult process. This is why recombinant methods as described above are preferred whenever possible. However, only limited amounts of the desired PUFA or LCPUFA and, in particular, DHA or EPA, can be produced with the aid of the above mentioned microorganisms, and, depending on the microorganism used, these are generally obtained as fatty acid mixtures of, for example, EPA, DPA and DHA.

Many attempts in the past have been made to make available genes which are involved in the synthesis of fatty acids or triglycerides for the production of oils in various organisms. Various desaturases have been described in the art; see, e.g., documents WO 91/13972, WO 93/11245, WO 94/11516, EP-A-0 550 162, WO 94/18337, WO 97/30582, WO 97/21340, WO 95/18222, EP-A-0 794 250, Stukey 1990, J. Biol. Chem., 265: 20144-20149, Wada 1990, Nature 347: 200-203, Huang 1999, Lipids 34: 649-659, WO 93/06712, U.S. Pat. No. 5,614,393, WO 96/21022, WO 00/21557, WO 99/27111, WO 98/46763, WO 98/46764, WO 98/46765, WO 99/64616 or WO 98/46776. These enzymes can be used for the production of unsaturated fatty acids. Thus, due to modern molecular biology, it has become possible to increase at least to some extent the content of the desired polyunsaturated fatty acids and, in particular, the PUFA or LCPUFA in a given organism. Elongases for the production of fatty acids are disclosed in the document WO2009/016202.

The biosynthesis of LCPUFA and the incorporation of LCPUFA into membrane lipids or triacylglycerides proceeds via various metabolic pathways (Abbadi 2001, European Journal of Lipid Science & Technology 103:106-113). In bacteria such as Vibrio, and microalgae, such as Schizochytrium, malonyl-CoA is converted into LCPUFA via an LCPUFA-producing polyketide synthase (Metz 2001, Science 293: 290-293; WO 00/42195; WO 98/27203; WO 98/55625). In microalgae, such as Phaeodactylum, and mosses, such as Physcomitrella, unsaturated fatty acids such as linoleic acid or linolenic acid are converted in a plurality of desaturation and elongation steps to give LCPUFA (Zank 2000, Biochemical Society Transactions 28: 654-658). Desaturation takes place either on acyl groups bound to Coenzyme A (acyl-CoA) or on acyl groups of membrane lipids, whereas elongation is biochemically restricted to acyl chains bound to CoA. In mammals, the biosynthesis of DHA comprises a chain shortening via beta-oxidation, in addition to desaturation and elongation steps. In microorganisms and lower plants, LCPUFA are present either exclusively in the form of membrane lipids, as is the case in Physcomitrella and Phaeodactylum, or in membrane lipids and triacylglycerides, as is the case in Schizochytrium and Mortierella. Incorporation of LCPUFA into lipids and oils, as well as the transfer of the fatty acid moiety (acyl group) between lipids and other molecular species such as acyl-CoA, is catalyzed by various acyltransferases and transacylases. These enzymes are, known to carry out the incorporation or interexchange of saturated and unsaturated fatty acids (Slabas 2001, J. Plant Physiology 158: 505-513, Frentzen 1998, Fett/Lipid 100: 161-166, Cases 1998, Proc. Nat. Acad. Sci. USA 95: 13018-13023). One group of acyltransferases having three distinct enzymatic activities are enzymes of the “Kennedy pathway”, which are located on the cytoplasmic side of the membrane system of the endoplasmic reticulum (ER). The ER-bound acyltransferases in the microsomal fraction use acyl-CoA as the activated form of fatty acids. Glycerol-3-phosphate acyltransferase (GPAT) catalyzes the incorporation of acyl groups at the sn-1 position of glycerol-3-phosphate. 1-Acylglycerol-3-phosphate acyltransferase, also known as lysophosphatidic acid acyltransferase (LPAAT), catalyze the incorporation of acyl groups at the sn-2 position of lysophosphatidic acid (LPA). After dephosphorylation of phosphatidic acid by phosphatidic acid phosphatase (PAP), diacylglycerol acyltransferase (DGAT) catalyzes the incorporation of acyl groups at the sn-3 position of diacylglycerols. Further enzymes directly involved in TAG biosynthesis—apart from the said Kennedy pathway enzymes—are the phospholipid diacylglycerol acyltransferase (PDAT), an enzyme that transfers acyl groups from the sn-2 position of membrane lipids to the sn-3 position of diacylglycerols, and diacylglyceroldiacylglycerol transacylase (DDAT), an enzyme that transfers acylgroups from the sn-2 position of one diacylglycerol-molecule to the sn-3 position of another diacylglycerol-molecule. Lysophospholipid acyltransferase (LPLAT) represents a class of acyltransferases that are capable of incorporating activated acyl groups from acyl-CoA to membrane lipids, and possibly catalyze also the reverse reaction. More specifically, LPLATs can have activity as lysophosphophatidylethanolamine acyltransferase (LPEAT) and lysophosphatidylcholine acyltransferase (LPCAT). Further enzymes, such as lecithin cholesterol acyltransferase (LCAT) can be involved in the transfer of acyl groups from membrane lipids into triacylglycerides, as well.

The documents WO 98/54302 and WO 98/54303 disclose a human LPAAT and its potential use for the therapy of diseases, as a diagnostic, and a method for identifying modulators of the human LPAAT. Moreover, a variety of acyltransferases with a wide range of enzymatic functions have been described in the documents WO 98/55632, WO 98/55631, WO 94/13814, WO 96/24674, WO 95/27791, WO 00/18889, WO 00/18889, WO 93/10241, Akermoun 2000, Biochemical Society Transactions 28: 713-715, Tumaney 1999, Biochimica et Biophysica Acta 1439: 47-56, Fraser 2000, Biochemical Society Transactions 28: 715-7718, Stymne 1984, Biochem. J. 223: 305-314, Yamashita 2001, Journal of Biological Chemistry 276: 26745-26752, and WO 00/18889.

Higher plants comprise PUFA, such as linoleic acid and linolenic acid. However, the LCPUFA ARA, EPA and DHA are not present in the seed oils of higher plants or only in traces (Ucciani: Nouveau Dictionnaire des Huiles Végétales. Technique & Documentation-Lavoisier, 1995. ISBN: 2-7430-0009-0). It is nevertheless highly desirable to produce LCPUFA in higher plants, preferably in oil seeds such as oilseed rape, linseed, sunflower and soybean, since large amounts of high-quality LCPUFA for the various aforementioned applications may be obtained thereby at low costs.

However, one drawback of using transgenic plants expressing various of the aforementioned desaturases and elongases involved in the synthesis of PUFA and LCPUFA is that the latter are not efficiently incorporated into triacylglycerides, but rather into membranes. Furthermore, efficient processing of a given acyl molecule-substrate, e.g. linoleic acid, by a plurality of desaturation and elongation steps towards the desired LCPUFA, e.g. ARA, EPA and/or DHA, is hindered by the requirement to transfer the acyl molecule and its derivatives generated by the elongation and desaturation reactions back and forth between membrane lipids and acyl-CoA. For this reason, intermediates towards desired LCPUFA are incorporated into oil before the synthesis of the desired LCPUFA is complete. These two problems are undesired for the following reasons: First, the main lipid fraction in oil seeds are triacylglycerides. This is why, for economical reasons, it is necessary to concentrate LCPUFA in triacylglycerides. Second, LCPUFA which are incorporated into membranes can modify the physical characteristics of the membranes and thus have harmful effects on the integrity and transport characteristics of the membranes and on the stress tolerance of plants. Third, for efficient LCPUFA synthesis, it is desirable to increase the flux of intermediate-LCPUFA between the two sites of biosynthesis—that are membrane lipids and acyl-CoA—and/or decrease the flux of intermediate-PUFA/-LCPUFA into oil. Transgenic plants which comprise and express genes coding for enzymes of LCPUFA biosynthesis and produce LCPUFA have been described, e.g., in DE 102 19 203 or WO2004/087902. However, these plants produce LCPUFA in amounts which require further optimization for processing the oils present in said plants. Moreover, it was proposed that delta 6 desaturated fatty acids may be shifted into the acyl-CoA pool for increasing efficiency of fatty acid elongation in plants (Singh 2005, Curr. Opin. Plant Biol, 8: 197-203). Another publication demonstrated in Arabidopsis, that the additional expression of RcDGAT2 from Ricinus communis increase the storage of hydroxyfatty acids produced by a Ricinus communis fatty acid hydroxylase 12 (FAH12) from 17% to 30% in the seed oil.

Accordingly, means for increasing the content of PUFA or LCPUFA, such as EPA and DHA, in triglycerides in, e.g., plant seed oils, are still highly desirable.

Thus, the present invention relates to a polynucleotide comprising a nucleic acid sequence elected from the group consisting of:

-   a) a nucleic acid sequence having a nucleotide sequence as shown in     any one of SEQ ID NOs: 52, 1, 4, 7, 10, 13, 16, 19, 22, 25, 28, 31,     34, 37, 40, 43, 46, 49, and 55; -   b) a nucleic acid sequence encoding a polypeptide having an amino     acid sequence as shown in any one of SEQ ID NOs: 53, 2, 5, 8, 11,     14, 17, 20, 23, 26, 29, 32, 35, 38, 41, 44, 47, 50, and 56; -   c) a nucleic acid sequence being at least 40% identical to the     nucleic acid sequence of a) or b), wherein said nucleic acid     sequence encodes a polypeptide having acyltransferase activity; -   d) a nucleic acid sequence encoding a polypeptide having     acyltransferase activity and having an amino acid sequence which is     at least 45% identical to the amino acid sequence of b); and -   e) a nucleic acid sequence which is capable of hybridizing under one     of the following sets of conditions to any one of a) to d), wherein     said nucleic acid sequence encodes a polypeptide having     acyltransferase activity: -   f) hybridization in 50 mM Tris, pH 7.6, 6×SSC, 5×Denhardt's, 1.0%     sodium dodecyl sulfat (SDS) 100 μg denaturated calf thymus DNA at     34° C. overnight and wash twice with 2×SSC, 0.5% SDS at room     temperature for 15 min each, repeat twice with 0.2×SSC, 0.5% SDS at     room temperature for 15 min each and then repeat twice with 0.2 SSC,     0.5% SDS at 50° C. for 15 min; -   g) hybridization in 6×SSPE (Sodium chloride Sodium Phosphate-EDTA),     5×Denhardt's solution, 0.5% SDS 100 μg denaturated calf thymus DNA     at 34° C. overnight and wash twice with 2×SSC, 0.5% SDS at room     temperature for 15 min each, repeat twice with 0.2×SSC, 0.5% SDS at     room temperature for 15 min each and then repeat twice with 0.2 SSC,     0.5% SDS at 50° C. for 15 min; -   h) hybridization in 20-30% formamide, 5×SSPE, 5×Denhardt's solution,     1% SDS 100 μg denaturated salmon sperm DNA at 34° C. overnight and     wash twice with 2×SSPE, 0.2% SDS at 42° C. for 15 min each, repeat     twice with 2×SSPE, 0.2% SDS at 55° C. for 30 min each and repeat     twice with 0.2 SSC, 0.5% SDS at 50° C. for 15 min; -   i) hybridization in 7% SDS, 0.5 M NaPO4, 1 mM EDTA at 50° C.     overnight and wash in 2×SSC, 0.1% SDS at 50° C. or 65° C.; -   j) hybridization in 7% SDS, 0.5 M NaPO4, 1 mM EDTA at 50° C.     overnight and wash in 1×SSC, 0.1% SDS at 50° C. or 65° C.; or -   k) hybridization in 7% SDS, 0.5 M NaPO4, 1 mM EDTA at 50° C.     overnight and wash in 0.1×SSC, 0.1% SDS at 50° C. or 65° C.

The term “polynucleotide” as used in accordance with the present invention relates to a polynucleotide comprising a nucleic acid sequence which encodes a polypeptide having acyltransferase activity. Preferably, the polypeptide encoded by the polynucleotide of the present invention having acyltransferas activity upon expression in a plant shall be capable of increasing the amount of PUFA and, in particular, LCPUFA esterified to triglycerides in, e.g., seed oils or the entire plant or parts thereof. Such an increase is, preferably, statistically significant when compared to a LCPUFA producing transgenic control plant which expresses the minimal set of desaturases and elongases requiered for LCPUFA synthesis but does not express the polynucleotide of the present invention. Such a transgenic plant may, preferably, express desaturases and elongases comprised by the vector LJB765 listed in table 11 of example 5 in WO2009/016202 or a similar set of desaturases and elongases required for DHA synthesis. Whether an increase is significant can be determined by statistical tests well known in the art including, e.g., Student's t-test. More preferably, the increase is an increase of the amount of triglycerides containing LCPUFA of at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45% or at least 50% compared to the said control. Preferably, the LCPUFA referred to before is a polyunsaturated fatty acid having a C-20, C-22 or C24 fatty acid body, more preferably, EPA or DHA, most preferably, DHA. Suitable assays for measuring the activities mentioned before are described in the accompanying Examples.

The term “acyltransferase activity” or “acyltransferase” as used herein encompasses all enymatic activities and enzymes which are capable of transferring or are involved in the transfer of PUFA and, in particular; LCPUFA from the acyl-CoA pool or the membrane phospholipis to the triglycerides, from the acyl-CoA pool to membrane lipids and from membrane lipids to the acyl-CoA pool by a transesterification process. It will be understood that this acyltransferase activity will result in an increase of the LCPUFA esterified to triglycerides in, e.g., seed oils. In particular, it is envisaged that these acyltransferases are capable of producing triglycerides having esterified EPA or even DHA, or that these acyltransferases are capable of enhancing synthesis of desired PUFA by increasing the flux for specific intermediates of the desired PUFA between the acyl-CoA pool (the site of elongation) and membrane lipids (the predominant site of desaturation). Specifically, acyltransferase activity as used herein relates to lysophospholipid acyltransferase (LPLAT) activity, preferably, lysophosphatidylcholine acyltransferase (LPCAT) or Lysophosphophatidylethanolamine acyltransferase (LPEAT) activity, lysophosphosphatidic acid acyltransferase (LPAAT) activity, glycerol-3-phosphate acyltransferase (GPAT) activity or diacylglycerol acyltransferase (DGAT), and, more preferably, to LPLAT, LPAAT, DGAT or GPAT activity.

More preferably, polynucleotides having a nucleic acid sequence as shown in SEQ ID NOs: 1, 4, and 7, encoding polypeptides having amino acid sequences as shown in SEQ ID NOs: 2, 5, and 8 or variants thereof, preferably, exhibit LPLAT activity. Polynucleotides having a nucleic acid sequence as shown in SEQ ID NOs: 10, and 13, encoding polypeptides having amino acid sequences as shown in SEQ ID NOs: 11, and 14 or variants thereof, preferably, exhibit LPAAT activity. Polynucleotides having a nucleic acid sequence as shown in SEQ ID NOs: 16, 19, 22, 25, 28, 31, 34, 37, 40, 43, 46, 49, 52, and 55, encoding polypeptides having amino acid sequences as shown in SEQ ID NOs: 17, 20, 23, 26, 29, 32, 35, 38, 41, 44, 47, 50, 53, and 56 or variants thereof, preferably, exhibit DGAT activity. A polynucleotide having a nucleic acid sequence as shown in SEQ ID NO: 55, encoding a polypeptide having amino acid sequences as shown in SEQ ID NO: 56 or variants thereof, preferably, exhibit GPAT activity.

A polynucleotide encoding a polypeptide having a acyltransferase activity as specified above has been obtained in accordance with the present invention, preferably, from Nannochloropsis oculata and/or Thraustochytrium aureum. However, orthologs, paralogs or other homologs may be identified from other species.

Thus, the term “polynucleotide” as used in accordance with the present invention further encompasses variants of the aforementioned specific polynucleotides representing orthologs, paralogs or other homologs of the polynucleotide of the present invention. Moreover, variants of the polynucleotide of the present invention also include artificially generated muteins. Said muteins include, e.g., enzymes which are generated by mutagenesis techniques and which exhibit improved or altered substrate specificity, or codon optimized polynucleotides. The polynucleotide variants, preferably, comprise a nucleic acid sequence characterized in that the sequence can be derived from the aforementioned specific nucleic acid sequences shown in any one of SEQ ID NOs: 52, 1, 4, 7, 10, 13, 16, 19, 22, 25, 28, 31, 34, 37, 40, 43, 46, 49, and 55 or by a polynucleotide encoding a polypeptide having an amino acid sequence as shown in any one of SEQ ID NOs: 53, 2, 5, 8, 11, 14, 17, 20, 23, 26, 29, 32, 35, 38, 41, 44, 47, 50, and 56 by at least one nucleotide substitution, addition and/or deletion, whereby the variant nucleic acid sequence shall still encode a polypeptide having a acyltransferase activity as specified above. Variants also encompass polynucleotides comprising a nucleic acid sequence which is capable of hybridizing to the aforementioned specific nucleic acid sequences, preferably, under stringent hybridization conditions. These stringent conditions are known to the skilled artisan and can be found in Current Protocols in Molecular Biology, John Wiley & Sons, N. Y. (1989), 6.3.1-6.3.6. A preferred example for stringent hybridization conditions are hybridization conditions in 6× sodium chloride/sodium citrate (=SSC) at approximately 45° C., followed by one or more wash steps in 0.2×SSC, 0.1% SDS at 50 to 65° C. The skilled artisan knows that these hybridization conditions differ depending on the type of nucleic acid and, for example when organic solvents are present, with regard to the temperature and concentration of the buffer. For example, under “standard hybridization conditions” the temperature differs depending on the type of nucleic acid between 42° C. and 58° C. in aqueous buffer with a concentration of 0.1 to 6×SSC (pH 7.2). If organic solvent is present in the abovementioned buffer, for example 50% formamide, the temperature under standard conditions is approximately 42° C. The hybridization conditions for DNA: DNA hybrids are, preferably, 0.1×SSC and 20° C. to 45° C., preferably between 30° C. and 45° C. and more preferably between 45° C. and 65° C. The hybridization conditions for DNA:RNA hybrids are, more preferably, 0.1×SSC and 30° C. to 55° C., most preferably between 45° C. and 65° C. The abovementioned hybridization temperatures are determined for example for a nucleic acid with approximately 100 bp (=base pairs) in length and a G+C content of 50% in the absence of formamide. The skilled artisan knows how to determine the hybridization conditions required by referring to textbooks such as the textbook mentioned above, or the following textbooks: Sambrook et al., “Molecular Cloning”, Cold Spring Harbor Laboratory, 1989; Hames and Higgins (Ed.) 1985, “Nucleic Acids Hybridization: A Practical Approach”, IRL Press at Oxford University Press, Oxford; Brown (Ed.) 1991, “Essential Molecular Biology: A Practical Approach”, IRL Press at Oxford University Press, Oxford.

In detail variants of polynucleotides still encode a polypeptide having a acyltransferase activity as specified above comprising a nucleic acid sequence which is capable of hybridizing preferably under conditions equivalent to hybridization in 50 mM Tris, pH 7.6, 6×SSC, 5×Denhardt's, 1.0% sodium dodecyl sulfat (SDS) 100 μg denaturated calf thymus DNA at 34° C. overnight, followed by washing twice with 2×SSC, 0.5% SDS at room temperature for 15 min each, then wash twice with 0.2×SSC, 0.5% SDS at room temperature for 15 min each and then wash twice with 0.2 SSC, 0.5% SDS at 50° C. for 15 min each to a nucleic acid described by any one of SEQ ID NOs: 52, 1, 4, 7, 10, 13, 16, 19, 22, 25, 28, 31, 34, 37, 40, 43, 46, 49, and 55 or the complement thereof.

More preferably, said variants of polynucleotides comprising a nucleic acid sequence which is capable of hybridizing under conditions equivalent to hybridization in 6×SSPE (Sodium chloride Sodium Phosphate-EDTA), 5×Denhardt's solution, 0.5% sodium dodecyl sulfat (SDS) 100 μg denaturated calf thymus DNA at 34° C. overnight, followed by washing twice with 2×SSC, 0.5% SDS at room temperature for 15 min each, then wash twice with 0.2×SSC, 0.5% SDS at room temperature for 15 min each and then wash twice with 0.2 SSC, 0.5% SDS at 50° C. for 15 min each to a nucleic acid described by any one of SEQ ID NOs: 52, 1, 4, 7, 10, 13, 16, 19, 22, 25, 28, 31, 34, 37, 40, 43, 46, 49, and 55 or the complement thereof.

Most preferably, said variants of polynucleotides comprising a nucleic acid sequence which is capable of hybridizing under conditions equivalent to hybridization in 20-30% formamide, 5×SSPE (Sodium chloride Sodium Phosphate-EDTA), 5×Denhardt's solution, 1% sodium dodecyl sulfat (SDS) 100 μg denaturated salmon sperm DNA at 34° C. overnight, followed by washing twice with 2×SSPE, 0.2% SDS at 42° C. for 15 min each, then wash twice with 2×SSPE, 0.2% SDS at 55° C. for 30 min each and then wash twice with 0.2 SSC, 0.5% SDS at 50° C. for 15 min each to a nucleic acid described by any one of SEQ ID NOs: 52, 1, 4, 7, 10, 13, 16, 19, 22, 25, 28, 31, 34, 37, 40, 43, 46, 49, and 55 or the complement thereof.

In another preferred embodiment aforementioned variants of polynucleotides still encode a polypeptide having a acyltransferase activity as specified above comprising a nucleic acid sequence which is capable of hybridizing under conditions equivalent to hybridization in 7% sodium dodecyl sulfate (SDS), 0.5 M NaPO4, 1 mM EDTA at 50° C. overnight with washing in 2×SSC, 0.1% SDS at 50° C. or 65° C., preferably 65° C. to a nucleic acid described by any one of SEQ ID NOs: 52, 1, 4, 7, 10, 13, 16, 19, 22, 25, 28, 31, 34, 37, 40, 43, 46, 49, and 55 or the complement thereof. In still another preferred embodiment, said variants of polynucleotides comprising a nucleic acid sequence which is capable of hybridizing under conditions equivalent to hybridization in 7% sodium dodecyl sulfate (SDS), 0.5 M NaPO4, 1 mM EDTA at 50° C. overnight with washing in 1×SSC, 0.1% SDS at 50° C. or 65° C., preferably 65° C. to a nucleotide sequence described by any one of SEQ ID NOs: 52, 1, 4, 7, 10, 13, 16, 19, 22, 25, 28, 31, 34, 37, 40, 43, 46, 49, and 55 or the complement thereof, most preferably, said variants of polynucleotides comprising a nucleic acid sequence which is capable of hybridizing under conditions equivalent to hybridization in 7% sodium dodecyl sulfate (SDS), 0.5 M NaPO4, 1 mM EDTA at 50° C. overnight with washing in 0.1×SSC, 0.1% SDS at 50° C. or 65° C., preferably 65° C. to a nucleic acid sequence described by any one of SEQ ID NOs: 52, 1, 4, 7, 10, 13, 16, 19, 22, 25, 28, 31, 34, 37, 40, 43, 46, 49, and 55 or the complement thereof.

The term “hybridization” as used herein includes “any process by which a strand of nucleic acid molecule joins with a complementary strand through base pairing.” (J. Coombs (1994) Dictionary of Biotechnology, Stockton Press, New York). Hybridization and the strength of hybridization (i.e., the strength of the association between the nucleic acid molecules) is impacted by such factors as the degree of complementarity between the nucleic acid molecules, stringency of the conditions involved, the Tm of the formed hybrid, and the G:C ratio within the nucleic acid molecules. As used herein, the term “Tm” is used in reference to the “melting temperature.” The melting temperature is the temperature at which a population of double-stranded nucleic acid molecules becomes half dissociated into single strands. The equation for calculating the Tm of nucleic acid molecules is well known in the art. As indicated by standard references, a simple estimate of the Tm value may be calculated by the equation: Tm=81.5+0.41(% G+C), when a nucleic acid molecule is in aqueous solution at 1 M NaCl [see e.g., Anderson and Young, Quantitative Filter Hybridization, in Nucleic Acid Hybridization (1985)]. Other references include more sophisticated computations, which take structural as well as sequence characteristics into account for the calculation of Tm. Stringent conditions, are known to those skilled in the art and can be found in Current Protocols in Molecular Biology, John Wiley & Sons, N.Y. (1989), 6.3.1-6.3.6.

A “complement” of a nucleic acid sequence as used herein refers to a nucleotide sequence whose nucleic acid molecules show total complementarity to the nucleic acid molecules of the nucleic acid sequence.

The term “Complementary” or “complementarity” refers to two nucleotide sequences which comprise antiparallel nucleotide sequences capable of pairing with one another (by the base-pairing rules) upon formation of hydrogen bonds between the complementary base residues in the antiparallel nucleotide sequences. For example, the sequence 5′-AGT-3′ is complementary to the sequence 5′-ACT-3′. Complementarity can be “partial” or “total.” “Partial” complementarity is where one or more nucleic acid bases are not matched according to the base pairing rules. “Total” or “complete” complementarity between nucleic acid molecules is where each and every nucleic acid base is matched with another base under the base pairing rules. The degree of complementarity between nucleic acid molecule strands has significant effects on the efficiency and strength of hybridization between nucleic acid molecule strands.

Alternatively, polynucleotide variants are obtainable by PCR-based techniques such as mixed oligonucleotide primer-based amplification of DNA, i.e. using degenerated primers against conserved domains of the polypeptides of the present invention. Conserved domains of the polypeptide of the present invention may be identified by a sequence comparison of the nucleic acid sequences of the polynucleotides or the amino acid sequences of the polypeptides of the present invention. Oligonucleotides suitable as PCR primers as well as suitable PCR conditions are described in the accompanying Examples. As a template, DNA or cDNA from bacteria, fungi, plants or animals may be used.

Further, variants include polynucleotides comprising nucleic acid sequences which are at least up to 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identical to the nucleic acid sequences shown in any one of SEQ ID NOs: 52, 1, 4, 7, 10, 13, 16, 19, 22, 25, 28, 31, 34, 37, 40, 43, 46, 49, and 55, preferably, encoding polypeptides retaining a acyltransferase activity as specified above.

Moreover, also encompassed are polynucleotides (derivatives) which comprise nucleic acid sequences encoding a polypeptide having an amino acid sequences which are at least up to 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identical to the amino acid sequences shown in any one of SEQ ID NOs: 53, 2, 5, 8, 11, 14, 17, 20, 23, 26, 29, 32, 35, 38, 41, 44, 47, 50, and 56, wherein the polypeptide, preferably, retains acyltransferase activity as specified above. The percent identity values are, preferably, calculated over the entire amino acid or nucleic acid sequence region. A series of programs based on a variety of algorithms is available to the skilled artisan for comparing different sequences. In a preferred embodiment, the percent identity between two amino acid sequences is determined using the Needleman and Wunsch algorithm (Needleman 1970, J. Mol. Biol. (48):444-453) which has been incorporated into the needle program in the EMBOSS software package (EMBOSS: The European Molecular Biology Open Software Suite, Rice, P., Longden, I., and Bleasby, A, Trends in Genetics 16(6), 276-277, 2000), using either a BLOSUM 45 or PAM250 scoring matrix for distantly related proteins, or either a BLOSUM 62 or PAM160 scoring matrix for closer related proteins, and a gap opening penalty of 16, 14, 12, 10, 8, 6, or 4 and a gap entension pentalty of 0.5, 1, 2, 3, 4, 5, or 6. Guides for local installation of the EMBOSS package as well as links to WEB-Services can be found at http://emboss.sourceforge.net. A preferred, non-limiting example of parameters to be used for aligning two amino acid sequences using the needle program are the default parameters, including the EBLOSUM62 scoring matrix, a gap opening penalty of 10 and a gap extension penalty of 0.5. In yet another preferred embodiment, the percent identity between two nucleotide sequences is determined using the needle program in the EMBOSS software package (EMBOSS: The European Molecular Biology Open Software Suite, Rice, P., Longden, I., and Bleasby, A, Trends in Genetics 16(6), 276-277, 2000), using the EDNAFULL scoring matrix and a gap opening penalty of 16, 14, 12, 10, 8, 6, or 4 and a gap extension penalty of 0.5, 1, 2, 3, 4, 5, or 6. A preferred, non-limiting example of parameters to be used in conjunction for aligning two amino acid sequences using the needle program are the default parameters, including the EDNAFULL scoring matrix, a gap opening penalty of 10 and a gap extension penalty of 0.5. The nucleic acid and protein sequences of the present invention can further be used as a “query sequence” to perform a search against public databases to, for example, identify other family members or related sequences. Such searches can be performed using the BLAST series of programs (version 2.2) of Altschul et al (Altschul 1990, J. Mol. Biol. 215:403-10). BLAST using acyltransferase nucleic acid sequences of the invention as query sequence can be performed with the BLASTn, BLASTx or the tBLASTx program using default parameters to obtain either nucleotide sequences (BLASTn, tBLASTx) or amino acid sequences (BLASTx) homologous to acyltransferase sequences of the invention. BLAST using acyltransferase protein sequences of the invention as query sequence can be performed with the BLASTp or the tBLASTn program using default parameters to obtain either amino acid sequences (BLASTp) or nucleic acid sequences (tBLASTn) homologous to acyltransferase sequences of the invention. To obtain gapped alignments for comparison purposes, Gapped BLAST using default parameters can be utilized as described in Altschul et al (Altschul 1997, Nucleic Acids Res. 25(17):3389-3402).

TABLE 1 Relation of sequence types of querry and hit sequences for various BLASt programs Input query Converted Converted Actual sequence Query Algorithm Hit Database DNA BLASTn DNA PRT BLASTp PRT DNA PRT BLASTx PRT PRT tBLASTn PRT DNA DNA PRT tBLASTx PRT DNA

A polynucleotide comprising a fragment of any of the aforementioned nucleic acid sequences is also encompassed as a polynucleotide of the present invention. The fragment shall encode a polypeptide which still has acyltransferase activity as specified above. Accordingly, the polypeptide may comprise or consist of the domains of the polypeptide of the present invention conferring the said biological activity. A fragment as meant herein, preferably, comprises at least 50, at least 100, at least 250 or at least 500 consecutive nucleotides of any one of the aforementioned nucleic acid sequences or encodes an amino acid sequence comprising at least 20, at least 30, at least 50, at least 80, at least 100 or at least 150 consecutive amino acids of any one of the aforementioned amino acid sequences.

The variant polynucleotides or fragments referred to above, preferably, encode polypeptides retaining acyltransferase activity to a significant extent, preferably, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80% or at least 90% of the acyltransferase activity exhibited by any of the polypeptide shown in any one of SEQ ID NOs: 2, 5, 8, 11, 14, 17, 20, 23, 26, 29, 32, 35, 38, 41, 44, 47, 50, 53, and 56 or derivative of any of these polypeptides. The activity may be tested as described in the accompanying examples.

The polynucleotides of the present invention either essentially consist of the aforementioned nucleic acid sequences or comprise the aforementioned nucleic acid sequences. Thus, they may contain further nucleic acid sequences as well. Preferably, the polynucleotide of the present invention may comprise in addition to an open reading frame further untranslated sequence at the 3′ and at the 5′ terminus of the coding gene region: at least 500, preferably 200, more preferably 100 nucleotides of the sequence upstream of the 5′ terminus of the coding region and at least 100, preferably 50, more preferably 20 nucleotides of the sequence downstream of the 3′ terminus of the coding gene region. Furthermore, the polynucleotides of the present invention may encode fusion proteins wherein one partner of the fusion protein is a polypeptide being encoded by a nucleic acid sequence recited above. Such fusion proteins may comprise as additional part other enzymes of the fatty acid or PUFA biosynthesis pathways, polypeptides for monitoring expression (e.g., green, yellow, blue or red fluorescent proteins, alkaline phosphatase and the like) or so called “tags” which may serve as a detectable marker or as an auxiliary measure for purification purposes. Tags for the different purposes are well known in the art and comprise FLAG-tags, 6-histidine-tags, MYC-tags and the like.

The polynucleotide of the present invention shall be provided, preferably, either as an isolated polynucleotide (i.e. purified or at least isolated from its natural context such as its natural gene locus) or in genetically modified or exogenously (i.e. artificially) manipulated form. An isolated polynucleotide can, for example, comprise less than approximately 5 kb, 4 kb, 3 kb, 2 kb, 1 kb, 0.5 kb or 0.1 kb of nucleotide sequences which naturally flank the nucleic acid molecule in the genomic DNA of the cell from which the nucleic acid is derived. The polynucleotide, preferably, is provided in the form of double or single stranded molecule. It will be understood that the present invention by referring to any of the aforementioned polynucleotides of the invention also refers to complementary or reverse complementary strands of the specific sequences or variants thereof referred to before. The polynucleotide encompasses DNA, including cDNA and genomic DNA, or RNA polynucleotides.

However, the present invention also pertains to polynucleotide variants which are derived from the polynucleotides of the present invention and are capable of interefering with the transcription or translation of the polynucleotides of the present invention. Such variant polynucleotides include anti-sense nucleic acids, ribozymes, siRNA molecules, morpholino nucleic acids (phosphorodiamidate morpholino oligos), triple-helix forming oligonucleotides, inhibitory oligonucleotides, or micro RNA molecules all of which shall specifically recognize the polynucleotide of the invention due to the presence of complementary or substantially complementary sequences. These techniques are well known to the skilled artisan. Suitable variant polynucleotides of the aforementioned kind can be readily designed based on the structure of the polynucleotides of this invention.

Moreover, comprised are also chemically modified polynucleotides including naturally occurring modified polynucleotides such as glycosylated or methylated polynucleotides or artificial modified ones such as biotinylated polynucleotides.

Advantageously, it has been found in accordance with the present invention that the polynucleotides encoding the above mentioned polypeptides having acyltransferase activity and, in particular, LPLAT, LPAAT, DGAT and/or GPAT activity, can be used for the manufacture of PUFA and, in particular, LCPUFA when expressed in a transgenic host organism or cell. Specifically, the aforementioned acyltransferase activities will allow for an increase of LCPUFA esterified to triglycerides in seed oils by shifting the said LCPUFA from the acyl-CoA pool (by polypeptides having LPAAT, DGAT or GPAT activity as specified above) and/or from the acyl-CoA pool/pospholipid pool to the phospholipid pool/acyl-CoA pool (by polypeptides having LPLAT as specified above) via transesterification. Surprisingly, it was found that the acyltransferases encoded by the polynucleotides of the present invention are also capable of efficiently shifting rather long and highly unsaturated LCPUFA towards the triglyceride pool or between the phospholipid pool and the acyl-CoA pool, in particular, even the long chain intermediates. More surprisingly even, DHA which is known to be incorporated in triglycerides only in very low amounts, if at all, can be efficiently transesterified to triglycerides by the acyltransferases of the invention.

In particular the LPLAT of the present invention can efficiently catalyse the transesterfication of 18:2n-6 from the sn2 position of phosphatidylcholine (PC) to CoA and/or from CoA to lysophosphatidylcholine (LPC), the transesterfication of 18:2n-6 from the sn2 position of phosphatidylethanolamine (PE) to CoA and/or from CoA to lysophosphatidylethanolamine (LPE), the transesterfication of 18:2n-6 from the sn2 position of phosphatidylserine (PS) to CoA and/or from CoA to lysophosphatidylserine (LPS), the transesterfication of 18:3n-6 from the sn2 position of phosphatidylcholine (PC) to CoA and/or from CoA to lysophosphatidylcholine (LPC), the transesterfication of 18:3n-6 from the sn2 position of phosphatidylethanolamine (PE) to CoA and/or from CoA to lysophosphatidylethanolamine (LPE), the transesterfication of 18:3n-6 from the sn2 position of phosphatidylserine (PS) to CoA and/or from CoA to lysophosphatidylserine (LPS), the transesterfication of 18:3n-3 from the sn2 position of phosphatidylcholine (PC) to CoA and/or from CoA to lysophosphatidylcholine (LPC), the transesterfication of 18:3n-3 from the sn2 position of phosphatidylethanolamine (PE) to CoA and/or from CoA to lysophosphatidylethanolamine (LPE), the transesterfication of 18:3n-3 from the sn2 position of phosphatidylserine (PS) to CoA and/or from CoA to lysophosphatidylserine (LPS), transesterfication of 18:4n-3 from the sn2 position of phosphatidylcholine (PC) to CoA and/or from CoA to lysophosphatidylcholine (LPC), the transesterfication of 18:4n-3 from the sn2 position of phosphatidylethanolamine (PE) to CoA and/or from CoA to lysophosphatidylethanolamine (LPE), the transesterfication of 18:4n-3 from the sn2 position of phosphatidylserine (PS) to CoA and/or from CoA to lysophosphatidylserine (LPS), the transesterfication of 20:3n-6 from the sn2 position of phosphatidylcholine (PC) to CoA and/or from CoA to lysophosphatidylcholine (LPC), the transesterfication of 20:3n-6 from the sn2 position of phosphatidylethanolamine (PE) to CoA and/or from CoA to lysophosphatidylethanolamine (LPE), the transesterfication of 20:3n-6 from the sn2 position of phosphatidylserine (PS) to CoA and/or from CoA to lysophosphatidylserine (LPS), the transesterfication of 20:4n-3 from the sn2 position of phosphatidylcholine (PC) to CoA and/or from CoA to lysophosphatidylcholine (LPC), the transesterfication of 20:4n-3 from the sn2 position of phosphatidylethanolamine (PE) to CoA and/or from CoA to lysophosphatidylethanolamine (LPE), the transesterfication of 20:4n-3 from the sn2 position of phosphatidylserine (PS) to CoA and/or from CoA to lysophosphatidylserine (LPS), the transesterfication of 20:4n-6 from the sn2 position of phosphatidylcholine (PC) to CoA and/or from CoA to lysophosphatidylcholine (LPC), the transesterfication of 20:4n-6 from the sn2 position of phosphatidylethanolamine (PE) to CoA and/or from CoA to lysophosphatidylethanolamine (LPE), the transesterfication of 20:4n-6 from the sn2 position of phosphatidylserine (PS) to CoA and/or from CoA to lysophosphatidylserine (LPS), the transesterfication of 20:5n-3 from the sn2 position of phosphatidylcholine (PC) to CoA and/or from CoA to lysophosphatidylcholine (LPC), the transesterfication of 20:5n-3 from the sn2 position of phosphatidylethanolamine (PE) to CoA and/or from CoA to lysophosphatidylethanolamine (LPE), the transesterfication of 20:5n-3 from the sn2 position of phosphatidylserine (PS) to CoA and/or from CoA to lysophosphatidylserine (LPS), the transesterfication of 22:5n-3 from the sn2 position of phosphatidylcholine (PC) to CoA and/or from CoA to lysophosphatidylcholine (LPC), the transesterfication of 22:5n-3 from the sn2 position of phosphatidylethanolamine (PE) to CoA and/or from CoA to lysophosphatidylethanolamine (LPE), the transesterfication of 22:5n-3 from the sn2 position of phosphatidylserine (PS) to CoA and/or from CoA to lysophosphatidylserine (LPS), the transesterfication of 22:6n-3 from the sn2 position of phosphatidylcholine (PC) to CoA and/or from CoA to lysophosphatidylcholine (LPC), the transesterfication of 22:6n-3 from the sn2 position of phosphatidylethanolamine (PE) to CoA and/or from CoA to lysophosphatidylethanolamine (LPE) and/or the transesterfication of 22:6n-3 from the sn2 position of phosphatidylserine (PS) to CoA and/or from CoA to lysophosphatidylserine (LPS).

Preferably the LPAAT of the present invention can efficiently catalyse the transesterfication of 18:2n-6 from CoA to the sn2 position of lysophosphatidic acid (LPA), the transesterfication of 18:3n-6 from CoA to the sn2 position of lysophosphatidic acid (LPA), the transesterfication of 18:3n-3 from CoA to the sn2 position of lysophosphatidic acid (LPA) and/or the transesterfication of 18:4n-6 from CoA to the sn2 position of lysophosphatidic acid (LPA).

More preferably the LPAAT of the present invention can efficiently catalyse the transesterfication of 20:3n-6 from CoA to the sn2 position of lysophosphatidic acid (LPA), transesterfication of 20:4n-3 from CoA to the sn2 position of lysophosphatidic acid (LPA) and/or the transesterfication of 22:5n-3 from CoA to the sn2 position of lysophosphatidic acid (LPA).

Most preferably the LPAAT of the present invention can efficiently catalyse the transesterfication of 20:4n-6 from CoA to the sn2 position of lysophosphatidic acid (LPA), the transesterfication of 20:5n-3 from CoA to the sn2 position of lysophosphatidic acid (LPA) and/or the transesterfication of 22:6n-3 from CoA to the sn2 position of lysophosphatidic acid (LPA).

Preferably the GPAT of the present invention can efficiently catalyse the transesterfication of 18:2n-6 from CoA to the sn1 position of glycerole-3-phosphate (G3P),the transesterfication of 18:3n-6 from CoA to the sn1 position of glycerole-3-phosphate (G3P), the transesterfication of 18:3n-3 from CoA to the sn1 position of glycerole-3-phosphate (G3P) and/or the transesterfication of 18:4n-6 from CoA to the sn1 position of glycerole-3-phosphate (G3P).

More preferably the GPAT of the present invention can efficiently catalyse the transesterfication of 20:3n-6 from CoA to the sn1 position of glycerole-3-phosphate (G3P), the transesterfication of 20:4n-3 from CoA to the sn1 position of glycerole-3-phosphate (G3P) and/or the transesterfication of 22:5n-3 from CoA to the sn1 position of glycerole-3-phosphate (G3P).

Most preferably the GPAT of the present invention can efficiently catalyse the transesterfication of 20:4n-6 from CoA to the sn1 position of glycerole-3-phosphate (G3P), the transesterfication of 20:5n-3 from CoA to the sn1 position of glycerole-3-phosphate (G3P) and/or the transesterfication of 22:6n-3 from CoA to the sn1 position of glycerole-3-phosphate (G3P).

Preferably the DGAT of the present invention can efficiently catalyse the transesterfication of 18:2n-6 from CoA to the sn3 position of Diacylglycerol (DAG), transesterfication of 18:3n-6 from CoA to the sn3 position of Diacylglycerol (DAG), the transesterfication of 18:3n-3 from CoA to the sn3 position of Diacylglycerol (DAG) and/or the transesterfication of 18:4n-6 from CoA to the sn3 position of Diacylglycerol (DAG).

More preferably the DGAT of the present invention can efficiently catalyse the transesterfication of 20:3n-6 from CoA to the sn3 position of Diacylglycerol (DAG), the transesterfication of 20:4n-3 from CoA to the sn3 position of Diacylglycerol (DAG) and/or the transesterfication of 22:5n-3 from CoA to the sn3 position of Diacylglycerol (DAG).

Most preferably the DGAT of the present invention can efficiently catalyse the transesterfication of 20:4n-6 from CoA to the sn3 position of Diacylglycerol (DAG), the transesterfication of 20:5n-3 from CoA to the sn3 position of Diacylglycerol (DAG) and/or the transesterfication of 22:6n-3 from CoA to the sn3 position of Diacylglycerol (DAG).

The activity of the LPLAT, LPAAT, GPAT or DGAT of the present invention is useful for the specificity of a fatty acid. This fatty acid specificity is useful to generate an artificially ARA-specificity preferably. More preferably the activity of the LPLAT, LPAAT, GPAT or DGAT of the present invention is useful to generate an artificially EPA-specificity. Most preferably the activity of the LPLAT, LPAAT, GPAT or DGAT of the present invention is useful to generate an artificially DHA-specificity.

In a preferred embodiment of the polynucleotide of the present invention, said polynucleotide further comprises an expression control sequence operatively linked to the said nucleic acid sequence.

The term “expression control sequence” as used herein refers to a nucleic acid sequence which is capable of governing, i.e. initiating and controlling, transcription of a nucleic acid sequence of interest, in the present case the nucleic sequences recited above. Such a sequence usually comprises or consists of a promoter or a combination of a promoter and enhancer sequences. Expression of a polynucleotide comprises transcription of the nucleic acid molecule, preferably, into a translatable mRNA. Additional regulatory elements may include transcriptional as well as translational enhancers. The following promoters and expression control sequences may be, preferably, used in an expression vector according to the present invention. The cos, tac, trp, tet, trp-tet, Ipp, lac, lpp-lac, lacIq, T7, T5, T3, gal, trc, ara, SP6, λ-PR or λ-PL promoters are, preferably, used in Gram-negative bacteria. For Gram-positive bacteria, promoters amy and SPO2 may be used. From yeast or fungal promoters ADC1, AOX1r, GAL1, MFα, AC, P-60, CYC1, GAPDH, TEF, rp28, ADH are, preferably, used. For animal cell or organism expression, the promoters CMV-, SV40-, RSV-promoter (Rous sarcoma virus), CMV-enhancer, SV40-enhancer are preferably used. From plants the promoters CaMV/35S (Franck 1980, Cell 21: 285-294], PRP1 (Ward 1993, Plant. Mol. Biol. 22), SSU, OCS, lib4, usp, STLS1, B33, nos or the ubiquitin or phaseolin promoter. Also preferred in this context are inducible promoters, such as the promoters described in EP 0 388 186 A1 (i.e. a benzylsulfonamide-inducible promoter), Gatz 1992, Plant J. 2:397-404 (i.e. a tetracyclin-inducible promoter), EP 0 335 528 A1 (i.e. a abscisic-acid-inducible promoter) or WO 93/21334 (i.e. a ethanol- or cyclohexenol-inducible promoter). Further suitable plant promoters are the promoter of cytosolic FBPase or the ST-LSI promoter from potato (Stockhaus 1989, EMBO J. 8, 2445), the phosphoribosyl-pyrophosphate amidotransferase promoter from Glycine max (Genbank accession No. U87999) or the node-specific promoter described in EP 0 249 676 A1. Particularly preferred are promoters which enable the expression in tissues which are involved in the biosynthesis of fatty acids. Also particularly preferred are seed-specific promoters such as the USP promoter in accordance with the practice, but also other promoters such as the LeB4, DC3, phaseolin or napin promoters. Further especially preferred promoters are seed-specific promoters which can be used for monocotyledonous or dicotyledonous plants and which are described in U.S. Pat. No. 5,608,152 (napin promoter from oilseed rape), WO 98/45461 (oleosin promoter from Arabidopsis, U.S. Pat. No. 5,504,200 (phaseolin promoter from Phaseolus vulgaris), WO 91/13980 (Bce4 promoter from Brassica), by Baeumlein et al., Plant J., 2, 2, 1992:233-239 (LeB4 promoter from a legume), these promoters being suitable for dicots. The following promoters are suitable for monocots: Ipt-2 or Ipt-1 promoter from barley (WO 95/15389 and WO 95/23230), hordein promoter from barley and other promoters which are suitable and which are described in WO 99/16890. In principle, it is possible to use all natural promoters together with their regulatory sequences, such as those mentioned above, for the novel process. Likewise, it is possible and advantageous to use synthetic promoters, either additionally or alone, especially when they mediate a seed-specific expression, such as, for example, as described in WO 99/16890. In a particular embodiment, seed-specific promoters are utilized to enhance the production of the desired PUFA or LCPUFA.

The term “operatively linked” as used herein means that the expression control sequence and the nucleic acid of interest are linked so that the expression of the said nucleic acid of interest can be governed by the said expression control sequence, i.e. the expression control sequence shall be functionally linked to the said nucleic acid sequence to be expressed. Accordingly, the expression control sequence and, the nucleic acid sequence to be expressed may be physically linked to each other, e.g., by inserting the expression control sequence at the 5′ end of the nucleic acid sequence to be expressed. Alternatively, the expression control sequence and the nucleic acid to be expressed may be merely in physical proximity so that the expression control sequence is capable of governing the expression of at least one nucleic acid sequence of interest. The expression control sequence and the nucleic acid to be expressed are, preferably, separated by not more than 500 bp, 300 bp, 100 bp, 80 bp, 60 bp, 40 bp, 20 bp, 10 bp or 5 bp.

In a further preferred embodiment of the polynucleotide of the present invention, said polynucleotide further comprises a terminator sequence operatively linked to the nucleic acid sequence.

The term “terminator” as used herein refers to a nucleic acid sequence which is capable of terminating transcription. These sequences will cause dissociation of the transcription machinery from the nucleic acid sequence to be transcribed. Preferably, the terminator shall be active in plants and, in particular, in plant seeds. Suitable terminators are known in the art and, preferably, include polyadenylation signals such as the SV40-poly-A site or the tk-poly-A site or one of the plant specific signals indicated in Loke et al. 2005, Plant Physiol 138, pp. 1457-1468, downstream of the nucleic acid sequence to be expressed.

The present invention also relates to a vector comprising the polynucleotide of the present invention.

The term “vector”, preferably, encompasses phage, plasmid, viral vectors as well as artificial chromosomes, such as bacterial or yeast artificial chromosomes. Moreover, the term also relates to targeting constructs which allow for random or site-directed integration of the targeting construct into genomic DNA. Such target constructs, preferably, comprise DNA of sufficient length for either homolgous or heterologous recombination as described in detail below. The vector encompassing the polynucleotide of the present invention, preferably, further comprises selectable markers for propagation and/or selection in a host. The vector may be incorporated into a host cell by various techniques well known in the art. If introduced into a host cell, the vector may reside in the cytoplasm or may be incorporated into the genome. In the latter case, it is to be understood that the vector may further comprise nucleic acid sequences which allow for homologous recombination or heterologous insertion. Vectors can be introduced into prokaryotic or eukaryotic cells via conventional transformation or transfection techniques. The terms “transformation” and “transfection”, conjugation and transduction, as used in the present context, are intended to comprise a multiplicity of prior-art processes for introducing foreign nucleic acid (for example DNA) into a host cell, including calcium phosphate, rubidium chloride or calcium chloride coprecipitation, DEAE-dextran-mediated transfection, lipofection, natural competence, carbon-based clusters, chemically mediated transfer, electroporation or particle bombardment. Suitable methods for the transformation or transfection of host cells, including plant cells, can be found in Sambrook et al. (Molecular Cloning: A Laboratory Manual, 2^(nd) ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989) and other laboratory manuals, such as Methods in Molecular Biology, 1995, Vol. 44, Agrobacterium protocols, Ed.: Gartland and Davey, Humana Press, Totowa, N.J. Alternatively, a plasmid vector may be introduced by heat shock or electroporation techniques. Should the vector be a virus, it may be packaged in vitro using an appropriate packaging cell line prior to application to host cells.

Preferably, the vector referred to herein is suitable as a cloning vector, i.e. replicable in microbial systems. Such vectors ensure efficient cloning in bacteria and, preferably, yeasts or fungi and make possible the stable transformation of plants. Those which must be mentioned are, in particular, various binary and co-integrated vector systems which are suitable for the T-DNA-mediated transformation. Such vector systems are, as a rule, characterized in that they contain at least the vir genes, which are required for the Agrobacterium-mediated transformation, and the sequences which delimit the T-DNA (T-DNA border). These vector systems, preferably, also comprise further cis-regulatory regions such as promoters and terminators and/or selection markers with which suitable transformed host cells or organisms can be identified. While co-integrated vector systems have vir genes and T-DNA sequences arranged on the same vector, binary systems are based on at least two vectors, one of which bears vir genes, but no T-DNA, while a second one bears T-DNA, but no vir gene. As a consequence, the last-mentioned vectors are relatively small, easy to manipulate and can be replicated both in E. coli and in Agrobacterium. These binary vectors include vectors from the pBIB-HYG, pPZP, pBecks, pGreen series. Preferably used in accordance with the invention are Bin19, pBI101, pBinAR, pGPTV and pCAMBIA. An overview of binary vectors and their use can be found in Hellens et al, Trends in Plant Science (2000) 5, 446-451. Furthermore, by using appropriate cloning vectors, the polynucleotides can be introduced into host cells or organisms such as plants or animals and, thus, be used in the transformation of plants, such as those which are published, and cited, in: Plant Molecular Biology and Biotechnology (CRC Press, Boca Raton, Fla.), chapter 6/7, pp. 71-119 (1993); F. F. White, Vectors for Gene Transfer in Higher Plants; in: Transgenic Plants, vol. 1, Engineering and Utilization, Ed.: Kung and R. Wu, Academic Press, 1993, 15-38; B. Jenes et al., Techniques for Gene Transfer, in: Transgenic Plants, vol. 1, Engineering and Utilization, Ed.: Kung and R. Wu, Academic Press (1993), 128-143; Potrykus 1991, Annu. Rev. Plant Physiol. Plant Molec. Biol. 42, 205-225.

More preferably, the vector of the present invention is an expression vector. In such an expression vector, i.e. a vector which comprises the polynucleotide of the invention having the nucleic acid sequence operatively linked to an expression control sequence (also called “expression cassette”) allowing expression in prokaryotic or eukaryotic cells or isolated fractions thereof. Suitable expression vectors are known in the art such as Okayama-Berg cDNA expression vector pcDV1 (Pharmacia), pCDM8, pRc/CMV, pcDNA1, pcDNA3 (Invitrogene) or pSPORT1 (GIBCO BRL). Further examples of typical fusion expression vectors are pGEX (Pharmacia Biotech Inc; Smith 1988, Gene 67:31-40), pMAL (New England Biolabs, Beverly, Mass.) and pRIT5 (Pharmacia, Piscataway, N.J.), where glutathione S-transferase (GST), maltose E-binding protein and protein A, respectively, are fused with the recombinant target protein. Examples of suitable inducible nonfusion E. coli expression vectors are, inter alia, pTrc (Amann 1988, Gene 69:301-315) and pET 11d (Studier 1990, Methods in Enzymology 185, 60-89). The target gene expression of the pTrc vector is based on the transcription from a hybrid trp-lac fusion promoter by host RNA polymerase. The target gene expression from the pET 11d vector is based on the transcription of a T7-gn10-lac fusion promoter, which is mediated by a coexpressed viral RNA polymerase (T7 gn1). This viral polymerase is provided by the host strains BL21 (DE3) or HMS174 (DE3) from a resident λ-prophage which harbors a T7 gn1 gene under the transcriptional control of the lacUV 5 promoter. The skilled artisan is familiar with other vectors which are suitable in prokaryotic organisms; these vectors are, for example, in E. coli, pLG338, pACYC184, the pBR series such as pBR322, the pUC series such as pUC18 or pUC19, the M113mp series, pKC30, pRep4, pHS1, pHS2, pPLc236, pMBL24, pLG200, pUR290, pIN-III113-β1, λgt11 or pBdCl, in Streptomyces pIJ101, pIJ364, pIJ702 or pIJ361, in Bacillus pUB110, pC194 or pBD214, in Corynebacterium pSA77 or pAJ667. Examples of vectors for expression in the yeast S. cerevisiae comprise pYep Sec1 (Baldari 1987, Embo J. 6:229-234), pMFa (Kurjan 1982, Cell 30:933-943), pJRY88 (Schultz 1987, Gene 54:113-123) and pYES2 (Invitrogen Corporation, San Diego, Calif.). Vectors and processes for the construction of vectors which are suitable for use in other fungi, such as the filamentous fungi, comprise those which are described in detail in: van den Hondel, C. A. M. J. J., & Punt, P. J. (1991) “Gene transfer systems and vector development for filamentous fungi, in: Applied Molecular Genetics of fungi, J. F. Peberdy et al., Ed., pp. 1-28, Cambridge University Press: Cambridge, or in: More Gene Manipulations in Fungi (J. W. Bennett & L. L. Lasure, Ed., pp. 396-428: Academic Press: San Diego). Further suitable yeast vectors are, for example, pAG-1, YEp6, YEp13 or pEMBLYe23. As an alternative, the polynucleotides of the present invention can be also expressed in insect cells using baculovirus expression vectors. Baculovirus vectors which are available for the expression of proteins in cultured insect cells (for example Sf9 cells) comprise the pAc series (Smith 1983, Mol. Cell Biol. 3:2156-2165) and the pVL series (Lucklow 1989, Virology 170:31-39).

The polynucleotide of the present invention can be expressed in single-cell plant cells (such as algae), see Falciatore 1999, Marine Biotechnology 1 (3):239-251 and the references cited therein, and plant cells from higher plants (for example Spermatophytes, such as arable crops) by using plant expression vectors. Examples of plant expression vectors comprise those which are described in detail in: Becker 1992, Plant Mol. Biol. 20:1195-1197; Bevan 1984, Nucl. Acids Res. 12:8711-8721; Vectors for Gene Transfer in Higher Plants; in: Transgenic Plants, Vol. 1, Engineering and Utilization, Ed.: Kung and R. Wu, Academic Press, 1993, p. 15-38. A plant expression cassette, preferably, comprises regulatory sequences which are capable of controlling the gene expression in plant cells and which are functionally linked so that each sequence can fulfill its function, such as transcriptional termination, for example polyadenylation signals. Preferred polyadenylation signals are those which are derived from Agrobacterium tumefaciens T-DNA, such as the gene 3 of the Ti plasmid pTiACH5, which is known as octopine synthase (Gielen 1984, EMBO J. 3, 835) or functional equivalents of these, but all other terminators which are functionally active in plants are also suitable. Since plant gene expression is very often not limited to transcriptional levels, a plant expression cassette preferably comprises other functionally linked sequences such as translation enhancers, for example the overdrive sequence, which comprises the 5′-untranslated tobacco mosaic virus leader sequence, which increases the protein/RNA ratio (Gallie 1987, Nucl. Acids Research 15:8693-8711). As described above, plant gene expression must be functionally linked to a suitable promoter which performs the expression of the gene in a timely, cell-specific or tissue-specific manner. Promoters which can be used are constitutive promoters (Benfey 1989, EMBO J. 8:2195-2202) such as those which are derived from plant viruses such as 35S CAMV (Franck 1980, Cell 21:285-294), 19S CaMV (see U.S. Pat. No. 5,352,605 and WO 84/02913) or plant promoters such as the promoter of the Rubisco small subunit, which is described in U.S. Pat. No. 4,962,028. Other preferred sequences for the use in functional linkage in plant gene expression cassettes are targeting sequences which are required for targeting the gene product into its relevant cell compartment (for a review, see Kermode 1996, Crit. Rev. Plant Sci. 15, 4: 285-423 and references cited therein), for example into the vacuole, the nucleus, all types of plastids, such as amyloplasts, chloroplasts, chromoplasts, the extracellular space, the mitochondria, the endoplasmic reticulum, oil bodies, peroxisomes and other compartments of plant cells. As described above, plant gene expression can also be facilitated via a chemically inducible promoter (for a review, see Gatz 1997, Annu. Rev. Plant Physiol. Plant Mol. Biol., 48:89-108). Chemically inducible promoters are particularly suitable if it is desired that genes are expressed in a time-specific manner. Examples of such promoters are a salicylic-acid-inducible promoter (WO 95/19443), a tetracyclin-inducible promoter (Gatz 1992, Plant J. 2, 397-404) and an ethanol-inducible promoter. Promoters which respond to biotic or abiotic stress conditions are also suitable promoters, for example the pathogen-induced PRP1-gene promoter (Ward 1993, Plant Mol. Biol. 22:361-366), the heat-inducible hsp80 promoter from tomato (U.S. Pat. No. 5,187,267), the cold-inducible alpha-amylase promoter from potato (WO 96/12814) or the wound-inducible pinII promoter (EP 0 375 091 A). The promoters which are especially preferred are those which bring about the expression of genes in tissues and organs in which fatty acid, lipid and oil biosynthesis takes place, in seed cells such as the cells of endosperm and of the developing embryo. Suitable promoters are the napin gene promoter from oilseed rape (U.S. Pat. No. 5,608,152), the USP promoter from Vicia faba (Baeumlein 1991, Mol. Gen. Genet. 225 (3):459-67), the oleosin promoter from Arabidopsis (WO 98/45461), the phaseolin promoter from Phaseolus vulgaris (U.S. Pat. No. 5,504,200), the Bce4 promoter from Brassica (WO 91/13980) or the legumin B4 promoter (LeB4; Baeumlein 1992, Plant Journal, 2 (2):233-9), and promoters which bring about the seed-specific expression in monocotyledonous plants such as maize, barley, wheat, rye, rice and the like. Suitable promoters to be taken into consideration are the Ipt2 or Ipt1 gene promoter from barley (WO 95/15389 and WO 95/23230) or those which are described in WO 99/16890 (promoters from the barley hordein gene, the rice glutelin gene, the rice oryzin gene, the rice prolamin gene, the wheat gliadin gene, wheat glutelin gene, the maize zein gene, the oat glutelin gene, the sorghum kasirin gene, the rye secalin gene). Likewise, especially suitable are promoters which bring about the plastid-specific expression since plastids are the compartment in which the precursors and some end products of lipid biosynthesis are synthesized. Suitable promoters such as the viral RNA-polymerase promoter are described in WO 95/16783 and WO 97/06250, and the clpP promoter from Arabidopsis, described in WO 99/46394.

The abovementioned vectors are only a small overview of vectors to be used in accordance with the present invention. Further vectors are known to the skilled artisan and are described, for example, in: Cloning Vectors (Ed., Pouwels, P. H., et al., Elsevier, Amsterdam-New York-Oxford, 1985, ISBN 0 444 904018). For further suitable expression systems for prokaryotic and eukaryotic cells see the chapters 16 and 17 of Sambrook, loc cit.

It follows from the above that, preferably, said vector is an expression vector. More preferably, the said polynucleotide of the present invention is under the control of a seed-specific promoter in the vector of the present invention. A preferred seed-specific promoter as meant herein is selected from the group consisting of Conlinin 1, Conlinin 2, napin, LuFad3, USP, LeB4, Arc, Fae, ACP, LuPXR, and SBP. For details, see, e.g., US 2003-0159174.

Moreover, the present invention relates to a host cell comprising the polynucleotide or the vector of the present invention.

Preferably, said host cell is a plant cell and, more preferably, a plant cell obtained from an oilseed crop. More preferably, said oilseed crop is selected from the group consisting of flax (Linum sp.), rapeseed (Brassica sp.), soybean (Glycine and Soja sp.), sunflower (Helianthus sp.), cotton (Gossypium sp.), corn (Zea mays), olive (Olea sp.), safflower (Carthamus sp.), cocoa (Theobroma cacoa), peanut (Arachis sp.), hemp, camelina, crambe, oil palm, coconuts, groundnuts, sesame seed, castor bean, lesquerella, tallow tree, sheanuts, tungnuts, kapok fruit, poppy seed, jojoba seeds and perilla.

Also preferably, said host cell is a microorganism. More preferably, said microorganism is a bacterium, a fungus or algae. More preferably, it is selected from the group consisting of Candida, Cryptococcus, Lipomyces, Rhodosporidium, Yarrowia and Schizochytrium.

Moreover, a host cell according to the present invention may also be an animal cell. Preferably, said animal host cell is a host cell of a fish or a cell line obtained therefrom. More preferably, the fish host cell is from herring, salmon, sardine, redfish, eel, carp, trout, halibut, mackerel, zander or tuna.

It will be understood that if the host cell of the invention shall be applied for LCPUFA production, it shall be capable of carrying out desaturation and elongation steps on fatty acids. To produce the LCPUFA according to the invention, the C16- or C18-fatty acids must first be desaturated by the enzymatic activity of a desaturase and subsequently be elongated by at least two carbon atoms via an elongase. After one elongation cycle, this enzyme activity gives C18- or C20-fatty acids and after two or three elongation cycles C22- or C24-fatty acids. The activity of the desaturases and elongases used in the process according to the invention preferably leads to C18-, C20-, C22- and/or C24-fatty acids, advantageously with at least two double bonds in the fatty acid molecule, preferably with three, four or five double bonds, especially preferably to give C20- and/or C22-fatty acids with at least two double bonds in the fatty acid molecule, preferably with three, four or five double bonds in the molecule. After a first desaturation and the elongation have taken place, further desaturation steps such as, for example, one in the delta-5 position may take place. Products of the process according to the invention which are especially preferred are DGLA, ARA, EPA DPA and/or DHA, most preferably EPA and/or DHA. Desaturases and elongases which are required for this process may not always be present naturally in the host cell. Accordingly, the present invention, preferably, envisages a host cell which in addition to the polynucleotide of the present invention comprises polynucleotides encoding such desaturases and/or elongases as required depending on the selected organism. Preferred desaturases and/or elongases which shall be present in the host cell are at least one enzyme selected from the group consisting of: Δ-4-desaturase, Δ-5-desaturase, Δ-5-elongase, Δ-6-desaturase, Δ12-desaturase, Δ15-desaturase, ω3-desaturase and Δ-6-elongase. Especially prefered are the bifunctional d12d15-Desaturases d12d15Des(Ac) from Acanthamoeba castellanii (WO2007042510), d12d15Des(Cp) from Claviceps purpurea (WO2008006202) and d12d15Des(Lg)1 from Lottia gigantea (WO2009016202), the d12-Desaturases d12Des(Co) from Calendula officinalis (WO200185968), d12Des(Lb) from Laccaria bicolor (WO2009016202), d12Des(Mb) from Monosiga brevicollis (WO2009016202), d12Des(Mg) from Mycosphaerella graminicola (WO2009016202), d12Des(Nh) from Nectria haematococca (WO2009016202), d12Des(Ol) from Ostreococcus lucimarinus (WO2008040787), d12Des(Pb) from Phycomyces blakesleeanus (WO2009016202), d12Des(Ps) from Phytophthora sojae (WO2006100241) and d12Des(Tp) from Thalassiosira pseudonana (WO2006069710), the d15-Desaturases d15Des(Hr) from Helobdella robusta (WO2009016202), d15Des(Mc) from Microcoleus chthonoplastes (WO2009016202), d15Des(Mf) from Mycosphaerella fijiensis (WO2009016202), d15Des(Mg) from Mycosphaerella graminicola (WO2009016202) and d15Des(Nh)2 from Nectria haematococca (WO2009016202), the d4-Desaturases d4Des(Eg) from Euglena gracilis (WO2004090123), d4Des(Tc) from Thraustochytrium sp. (WO2002026946) and d4Des(Tp) from Thalassiosira pseudonana (WO2006069710), the d5-Desaturases d5Des(Ol)2 from Ostreococcus lucinnarinus (WO2008040787), d5Des(Pp) from Physcomitrella patens (WO2004057001), d5Des(Pt) from Phaeodactylum tricornutum (WO2002057465), d5Des(Tc) from Thraustochytrium sp. (WO2002026946), d5Des(Tp) from Thalassiosira pseudonana (WO2006069710) and the d6-Desaturases d6Des(Cp) from Ceratodon purpureus (WO2000075341), d6Des(Ol) from Ostreococcus lucimarinus (WO2008040787), d6Des(Ot) from Ostreococcus tauri (WO2006069710), d6Des(Pf) from Primula farinosa (WO2003072784), d6Des(Pir)_BO from Pythium irregulare (WO2002026946), d6Des(Pir) from Pythium irregulare (WO2002026946), d6Des(Plu) from Primula luteola (WO2003072784), d6Des(Pp) from Physcomitrella patens (WO200102591), d6Des(Pt) from Phaeodactylum tricornutum (WO2002057465), d6Des(Pv) from Primula vialii (WO2003072784) and d6Des(Tp) from Thalassiosira pseudonana (WO2006069710), the d8-Desaturases d8Des(Ac) from Acanthamoeba castellanii (EP1790731), d8Des(Eg) from Euglena gracilis (WO200034439) and d8Des(Pm) from Perkinsus marinus (WO2007093776), the o3-Desaturases o3Des(Pi) from Phytophthora infestans (WO2005083053), o3Des(Pir) from Pythium irregulare (WO2008022963), o3Des(Pir)2 from Pythium irregulare (WO2008022963) and o3Des(Ps) from Phytophthora sojae (WO2006100241), the bifunctional d5d6-elongases d5d6Elo(Om)2 from Oncorhynchus mykiss (WO2005012316), d5d6Elo(Ta) from Thraustochytrium aureum (WO2005012316) and d5d6Elo(Tc) from Thraustochytrium sp. (WO2005012316), the d5-elongases d5Elo(At) from Arabidopsis thaliana (WO2005012316), d5Elo(At)2 from Arabidopsis thaliana (WO2005012316), d5Elo(Ci) from Ciona intestinalis (WO2005012316), d5Elo(Ol) from Ostreococcus lucimarinus (WO2008040787), d5Elo(Ot) from Ostreococcus tauri (WO2005012316), d5Elo(Tp) from Thalassiosira pseudonana (WO2005012316) and d5Elo(XI) from Xenopus laevis (WO2005012316), the d6-elongases d6Elo(OI) from Ostreococcus lucimarinus (WO2008040787), d6Elo(Ot) from Ostreococcus tauri (WO2005012316), d6Elo(Pi) from Phytophthora infestans (WO2003064638), d6Elo(Pir) from Pythium irregulare (WO2009016208), d6Elo(Pp) from Physcomitrella patens (WO2001059128), d6Elo(Ps) from Phytophthora sojae (WO2006100241), d6Elo(Ps)2 from Phytophthora sojae (WO2006100241), d6Elo(Ps)3 from Phytophthora sojae (WO2006100241), d6Elo(Pt) from Phaeodactylum tricornutum (WO2005012316), d6Elo(Tc) from Thraustochytrium sp. (WO2005012316) and d6Elo(Tp) from Thalassiosira pseudonana (WO2005012316), the d9-elongases d9Elo(Ig) from Isochrysis galbana (WO2002077213), d9Elo(Pm) from Perkinsus marinus (WO2007093776) and d9Elo(Ro) from Rhizopus oryzae (WO2009016208).

The present invention also relates to a cell, preferably a host cell as specified above or a cell of a non-human organism specified elsewhere herein, said cell comprising a polynucleotide which is obtained from the polynucleotide of the present invention by a point mutation, a truncation, an inversion, a deletion, an addition, a substitution and homologous recombination. How to carry out such modifications to a polynucleotide is well known to the skilled artisan and has been described elsewhere in this specification in detail.

The present invention furthermore relates to a method for the manufacture of a polypeptide encoded by a polynucleotide of any the present invention comprising

-   a) cultivating the host cell of the invention under conditions which     allow for the production of said polypeptide; and -   b) obtaining the polypeptide from the host cell of step a).

Suitable conditions which allow for expression of the polynucleotide of the invention comprised by the host cell depend on the host cell as well as the expression control sequence used for governing expression of the said polynucleotide. These conditions and how to select them are very well known to those skilled in the art. The expressed polypeptide may be obtained, for example, by all conventional purification techniques including affinity chromatography, size exclusion chromatography, high pressure liquid chromatography (HPLC) and precipitation techniques including antibody precipitation. It is to be understood that the method may—although preferred—not necessarily yield an essentially pure preparation of the polypeptide. It is to be understood that depending on the host cell which is used for the aforementioned method, the polypeptides produced thereby may become posttranslationally modified or processed otherwise.

The present invention encompasses a polypeptide encoded by the polynucleotide of the present invention or which is obtainable by the aforementioned method.

The term “polypeptide” as used herein encompasses essentially purified polypeptides or polypeptide preparations comprising other proteins in addition. Further, the term also relates to the fusion proteins or polypeptide fragments being at least partially encoded by the polynucleotide of the present invention referred to above. Moreover, it includes chemically modified polypeptides. Such modifications may be artificial modifications or naturally occurring modifications such as phosphorylation, glycosylation, myristylation and the like (Review in Mann 2003, Nat. Biotechnol. 21, 255-261, review with focus on plants in Huber 2004, Curr. Opin. Plant Biol. 7, 318-322). Currently, more than 300 posttranslational modifications are known (see full ABFRC Delta mass list at http://www.abrf.org/index.cfm/dm.home). The polypeptide of the present invention shall exhibit the acyltransferase activities referred to above.

The present invention furthermore relates to an antibody or a fragment derived thereof as an antigen which specifically recognizes a polypeptide encoded by the nucleic acid sequences of the invention.

Antibodies against the polypeptides of the invention can be prepared by well known methods using a purified polypeptide according to the invention or a suitable fragment derived therefrom as an antigen. A fragment which is suitable as an antigen may be identified by antigenicity determining algorithms well known in the art. Such fragments may be obtained either from the polypeptide of the invention by proteolytic digestion or may be a synthetic peptide. Preferably, the antibody of the present invention is a monoclonal antibody, a polyclonal antibody, a single chain antibody, a chimerized antibody or a fragment of any of these antibodies, such as Fab, Fv or scFv fragments etc. Also comprised as antibodies by the present invention are bispecific antibodies, synthetic antibodies or chemically modified derivatives of any of the aforementioned antibodies. The antibody of the present invention shall specifically bind (i.e. does significantly not cross react with other polypeptides or peptides) to the polypeptide of the invention. Specific binding can be tested by various well known techniques. Antibodies or fragments thereof can be obtained by using methods which are described, e.g., in Harlow and Lane “Antibodies, A Laboratory Manual”, CSH Press, Cold Spring Harbor, 1988. Monoclonal antibodies can be prepared by the techniques originally described in Köhler 1975, Nature 256, 495, and Galfré 1981, Meth. Enzymol. 73, 3, which comprise the fusion of mouse myeloma cells to spleen cells derived from immunized mammals. The antibodies can be used, for example, for the immunoprecipitation, immunolocalization or purification (e.g., by affinity chromatography) of the polypeptides of the invention as well as for the monitoring of the presence of said variant polypeptides, for example, in recombinant organisms, and for the identification of proteins or compounds interacting with the proteins according to the invention.

Moreover, the present invention contemplates a non-human transgenic organism comprising the polynucleotide or the vector of the present invention.

Preferably, the non-human transgenic organism is a microorganism, more preferably the non-human transgenic organism is a fungus and most preferably the non-human transgenic organism is a plant, plant part, or plant seed. Preferred plants to be used for introducing the polynucleotide or the vector of the invention are plants which are capable of synthesizing fatty acids, such as all dicotyledonous or monocotyledonous plants, algae or mosses. It is to be understood that host cells derived from a plant may also be used for producing a plant according to the present invention. Preferred plants are selected from the group of the plant families Adelotheciaceae, Anacardiaceae, Asteraceae, Apiaceae, Betulaceae, Boraginaceae, Brassicaceae, Bromeliaceae, Caricaceae, Cannabaceae, Convolvulaceae, Chenopodiaceae, Crypthecodiniaceae, Cucurbitaceae, Ditrichaceae, Elaeagnaceae, Ericaceae, Euphorbiaceae, Fabaceae, Geraniaceae, Gramineae, Juglandaceae, Lauraceae, Leguminosae, Linaceae, Prasinophyceae or vegetable plants or ornamentals such as Tagetes. Examples which may be mentioned are the following plants selected from the group consisting of: Adelotheciaceae such as the genera Physcomitrella, such as the genus and species Physcomitrella patens, Anacardiaceae such as the genera Pistacia, Mangifera, Anacardium, for example the genus and species Pistacia vera [pistachio], Mangifer indica [mango] or Anacardium occidentale [cashew], Asteraceae, such as the genera Calendula, Carthamus, Centaurea, Cichorium, Cynara, Helianthus, Lactuca, Locusta, Tagetes, Valeriana, for example the genus and species Calendula officinalis [common marigold], Carthamus tinctorius [safflower], Centaurea cyanus [cornflower], Cichorium intybus [chicory], Cynara scolymus [artichoke], Helianthus annus [sunflower], Lactuca sativa, Lactuca crispa, Lactuca esculenta, Lactuca scariola L. ssp. sativa, Lactuca scariola L. var. integrata, Lactuca scariola L. var. integrifolia, Lactuca sativa subsp. romana, Locusta communis, Valeriana locusta [salad vegetables], Tagetes lucida, Tagetes erecta or Tagetes tenuifolia [african or french marigold], Apiaceae, such as the genus Daucus, for example the genus and species Daucus carota [carrot], Betulaceae, such as the genus Corylus, for example the genera and species Corylus avellana or Corylus colurna [hazelnut], Boraginaceae, such as the genus Borago, for example the genus and species Borago officinalis [borage], Brassicaceae, such as the genera Brassica, Melanosinapis, Sinapis, Arabadopsis, for example the genera and species Brassica napus, Brassica rapa ssp. [oilseed rape], Sinapis arvensis Brassica juncea, Brassica juncea var. juncea, Brassica juncea var. crispifolia, Brassica juncea var. foliosa, Brassica nigra, Brassica sinapioides, Melanosinapis communis [mustard], Brassica oleracea [fodder beet] or Arabidopsis thaliana, Bromeliaceae, such as the genera Anana, Bromelia (pineapple), for example the genera and species Anana comosus, Ananas ananas or Bromelia comosa [pineapple], Caricaceae, such as the genus Carica, such as the genus and species Carica papaya [pawpaw], Cannabaceae, such as the genus Cannabis, such as the genus and species Cannabis sativa [hemp], Convolvulaceae, such as the genera Ipomea, Convolvulus, for example the genera and species Ipomoea batatus, Ipomoea pandurata, Convolvulus batatas, Convolvulus tiliaceus, Ipomoea fastigiata, Ipomoea tiliacea, Ipomoea triloba or Convolvulus panduratus [sweet potato, batate], Chenopodiaceae, such as the genus Beta, such as the genera and species Beta vulgaris, Beta vulgaris var. altissima, Beta vulgaris var. Vulgaris, Beta maritima, Beta vulgaris var. perennis, Beta vulgaris var. conditiva or Beta vulgaris var. esculenta [sugarbeet], Crypthecodiniaceae, such as the genus Crypthecodinium, for example the genus and species Cryptecodinium cohnii, Cucurbitaceae, such as the genus Cucurbita, for example the genera and species Cucurbita maxima, Cucurbita mixta, Cucurbita pepo or Cucurbita moschata [pumpkin/squash], Cymbellaceae such as the genera Amphora, Cymbella, Okedenia, Phaeodactylum, Reimeria, for example the genus and species Phaeodactylum tricornutum, Ditrichaceae such as the genera Ditrichaceae, Astomiopsis, Ceratodon, Chrysoblastella, Ditrichum, Distichium, Eccremidium, Lophidion, Philibertiella, Pleuridium, Saelania, Trichodon, Skottsbergia, for example the genera and species Ceratodon antarcticus, Ceratodon columbiae, Ceratodon heterophyllus, Ceratodon purpureus, Ceratodon purpureus, Ceratodon purpureus ssp. convolutus, Ceratodon, purpureus spp. stenocarpus, Ceratodon purpureus var. rotundifolius, Ceratodon ratodon, Ceratodon stenocarpus, Chrysoblastella chilensis, Ditrichum ambiguum, Ditrichum brevisetum, Ditrichum crispatissimum, Ditrichum difficile, Ditrichum falcifolium, Ditrichum flexicaule, Ditrichum giganteum, Ditrichum heteromallum, Ditrichum lineare, Ditrichum lineare, Ditrichum montanum, Ditrichum montanum, Ditrichum pallidum, Ditrichum punctulatum, Ditrichum pusillum, Ditrichum pusillum var. tortile, Ditrichum rhynchostegium, Ditrichum schimperi, Ditrichum tortile, Distichium capillaceum, Distichium hagenii, Distichium inclinatum, Distichium macounii, Eccremidium floridanum, Eccremidium whiteleggei, Lophidion strictus, Pleuridium acuminatum, Pleuridium alternifolium, Pleuridium holdridgei, Pleuridium mexicanum, Pleuridium ravenelii, Pleuridium subulatum, Saelania glaucescens, Trichodon borealis, Trichodon cylindricus or Trichodon cylindricus var. oblongus, Elaeagnaceae such as the genus Elaeagnus, for example the genus and species Olea europaea [olive], Ericaceae such as the genus Kalmia, for example the genera and species Kalmia latifolia, Kalmia angustifolia, Kalmia microphylla, Kalmia polifolia, Kalmia occidentalis, Cistus chamaerhodendros or Kalmia lucida [mountain laurel], Euphorbiaceae such as the genera Manihot, Janipha, Jatropha, Ricinus, for example the genera and species Manihot utilissima, Janipha manihot, Jatropha manihot, Manihot aipil, Manihot dulcis, Manihot manihot, Manihot melanobasis, Manihot esculenta [manihot] or Ricinus communis [castor-oil plant], Fabaceae such as the genera Pisum, Albizia, Cathormion, Feuillea, Inga, Pithecolobium, Acacia, Mimosa, Medicajo, Glycine, Dolichos, Phaseolus, Soja, for example the genera and species Pisum sativum, Pisum arvense, Pisum humile [pea], Albizia berteriana, Albizia julibrissin, Albizia lebbeck, Acacia berteriana, Acacia littoralis, Albizia berteriana, Albizzia berteriana, Cathormion berteriana, Feuillea berteriana, Inga fragrans, Pithecellobium berterianum, Pithecellobium fragrans, Pithecolobium berterianum, Pseudalbizzia berteriana, Acacia julibrissin, Acacia nemu, Albizia nemu, Feuilleea julibrissin, Mimosa julibrissin, Mimosa speciosa, Sericanrda julibrissin, Acacia lebbeck, Acacia macrophylla, Albizia lebbek, Feuilleea lebbeck, Mimosa lebbeck, Mimosa speciosa [silk tree], Medicago sativa, Medicago falcata, Medicago varia [alfalfa], Glycine max Dolichos soja, Glycine gracilis, Glycine hispida, Phaseolus max, Soja hispida or Soja max [soybean], Funariaceae such as the genera Aphanorrhegma, Entosthodon, Funaria, Physcomitrella, Physcomitrium, for example the genera and species Aphanorrhegma serratum, Entosthodon attenuatus, Entosthodon bolanderi, Entosthodon bonplandii, Entosthodon californicus, Entosthodon drummondii, Entosthodon jamesonii, Entosthodon leibergii, Entosthodon neoscoticus, Entosthodon rubrisetus, Entosthodon spathulifolius, Entosthodon tucsoni, Funaria americana, Funaria bolanderi, Funaria calcarea, Funaria californica, Funaria calvescens, Funaria convoluta, Funaria flavicans, Funaria groutiana, Funaria hygrometrica, Funaria hygrometrica var. arctica, Funaria hygrometrica var. calvescens, Funaria hygrometrica var. convoluta, Funaria hygrometrica var. muralis, Funaria hygrometrica var. utahensis, Funaria microstoma, Funaria microstoma var. obtusifolia, Funaria muhlenbergii, Funaria orcuttii, Funaria plano-convexa, Funaria polaris, Funaria ravenelii, Funaria rubriseta, Funaria serrata, Funaria sonorae, Funaria sublimbatus, Funaria tucsoni, Physcomitrella californica, Physcomitrella patens, Physcomitrella readeri, Physcomitrium australe, Physcomitrium californicum, Physcomitrium collenchymatum, Physcomitrium coloradense, Physcomitrium cupuliferum, Physcomitrium drummondii, Physcomitrium eurystomum, Physcomitrium flexifolium, Physcomitrium hookeri, Physcomitrium hookeri var. serratum, Physcomitrium immersum, Physcomitrium kellermanii, Physcomitrium megalocarpum, Physcomitrium pyriforme, Physcomitrium pyriforme var. serratum, Physcomitrium rufipes, Physcomitrium sandbergii, Physcomitrium subsphaericum, Physcomitrium washingtoniense, Geraniaceae, such as the genera Pelargonium, Cocos, Oleum, for example the genera and species Cocos nucifera, Pelargonium grossularioides or Oleum cocois [coconut], Gramineae, such as the genus Saccharum, for example the genus and species Saccharum officinarum, Juglandaceae, such as the genera Juglans, Wallia, for example the genera and species Juglans regia, Juglans ailanthifolia, Juglans sieboldiana, Juglans cinerea, Wallia cinerea, Juglans bixbyi, Juglans californica, Juglans hindsii, Juglans intermedia, Juglans jamaicensis, Juglans major, Juglans microcarpa, Juglans nigra or Wallia nigra [walnut], Lauraceae, such as the genera Persea, Laurus, for example the genera and species Laurus nobilis [bay], Persea americana, Persea gratissima or Persea persea [avocado], Leguminosae, such as the genus Arachis, for example the genus and species Arachis hypogaea [peanut], Linaceae, such as the genera Linum, Adenolinum, for example the genera and species Linum usitatissimum, Linum humile, Linum austriacum, Linum bienne, Linum angustifolium, Linum catharticum, Linum flavum, Linum grandiflorum, Adenolinum grandiflorum, Linum lewisii, Linum narbonense, Linum perenne, Linum perenne var. lewisii, Linum pratense or Linum trigynum [linseed], Lythrarieae, such as the genus Punica, for example the genus and species Punica granatum [pomegranate], Malvaceae, such as the genus Gossypium, for example the genera and species Gossypium hirsutum, Gossypium arboreum, Gossypium barbadense, Gossypium herbaceum or Gossypium thurberi [cotton], Marchantiaceae, such as the genus Marchantia, for example the genera and species Marchantia berteroana, Marchantia foliacea, Marchantia macropora, Musaceae, such as the genus Musa, for example the genera and species Musa nana, Musa acuminata, Musa paradisiaca, Musa spp. [banana], Onagraceae, such as the genera Camissonia, Oenothera, for example the genera and species Oenothera biennis or Camissonia brevipes [evening primrose], Palmae, such as the genus Elacis, for example the genus and species Elaeis guineensis [oil palm], Papaveraceae, such as the genus Papaver, for example the genera and species Papaver orientale, Papaver rhoeas, Papaver dubium [poppy], Pedaliaceae, such as the genus Sesamum, for example the genus and species Sesamum indicum [sesame], Piperaceae, such as the genera Piper, Artanthe, Peperomia, Steffensia, for example the genera and species Piper aduncum, Piper amalago, Piper angustifolium, Piper auritum, Piper betel, Piper cubeba, Piper longum, Piper nigrum, Piper retrofractum, Artanthe adunca, Artanthe elongata, Peperomia elongata, Piper elongatum, Steffensia elongata [cayenne pepper], Poaceae, such as the genera Hordeum, Secale, Avena, Sorghum, Andropogon, Holcus, Panicum, Oryza, Zea (maize), Triticum, for example the genera and species Hordeum vulgare, Hordeum jubatum, Hordeum murinum, Hordeum secalinum, Hordeum distichon, Hordeum aegiceras, Hordeum hexastichon, Hordeum hexastichum, Hordeum irregulare, Hordeum sativum, Hordeum secalinum [barley], Secale cereale [rye], Avena sativa, Avena fatua, Avena byzantina, Avena fatua var. sativa, Avena hybrida [oats], Sorghum bicolor, Sorghum halepense, Sorghum saccharatum, Sorghum vulgare, Andropogon drummondii, Holcus bicolor, Holcus sorghum, Sorghum aethiopicum, Sorghum arundinaceum, Sorghum caffrorum, Sorghum cernuum, Sorghum dochna, Sorghum drummondii, Sorghum durra, Sorghum guineense, Sorghum lanceolatum, Sorghum nervosum, Sorghum saccharatum, Sorghum subglabrescens, Sorghum verticilliflorum, Sorghum vulgare, Holcus halepensis, Sorghum miliaceum, Panicum militaceum [millet], Oryza sativa, Oryza latifolia [rice], Zea mays [maize], Triticum aestivum, Triticum durum, Triticum turgidum, Triticum hybernum, Triticum macha, Triticum sativum or Triticum vulgare [wheat], Porphyridiaceae, such as the genera Chroothece, Flintiella, Petrovanella, Porphyridium, Rhodella, Rhodosorus, Vanhoeffenia, for example the genus and species Porphyridium cruentum, Proteaceae, such as the genus Macadamia, for example the genus and species Macadamia intergrifolia [macadamia], Prasinophyceae such as the genera Nephroselmis, Prasinococcus, Scherffelia, Tetraselmis, Mantoniella, Ostreococcus, for example the genera and species Nephroselmis olivacea, Prasinococcus capsulatus, Scherffelia dubia, Tetraselmis chui, Tetraselmis suecica, Mantoniella squamata, Ostreococcus tauri, Rubiaceae such as the genus Cofea, for example the genera and species Cofea spp., Coffea arabica, Coffea canephora or Coffea liberica [coffee], Scrophulariaceae such as the genus Verbascum, for example the genera and species Verbascum blattaria, Verbascum chaixii, Verbascum densiflorum, Verbascum lagurus, Verbascum longifolium, Verbascum lychnitis, Verbascum nigrum, Verbascum olympicum, Verbascum phlomoides, Verbascum phoenicum, Verbascum pulverulentum or Verbascum thapsus [mullein], Solanaceae such as the genera Capsicum, Nicotiana, Solanum, Lycopersicon, for example the genera and species Capsicum annuum, Capsicum annuum var. glabriusculum, Capsicum frutescens [pepper], Capsicum annuum [paprika], Nicotiana tabacum, Nicotiana alata, Nicotiana attenuata, Nicotiana glauca, Nicotiana langsdorffii, Nicotiana obtusifolia, Nicotiana quadrivalvis, Nicotiana repanda, Nicotiana rustica, Nicotiana sylvestris [tobacco], Solanum tuberosum [potato], Solanum melongena [eggplant], Lycopersicon esculentum, Lycopersicon lycopersicum, Lycopersicon pyriforme, Solanum integrifolium or Solanum lycopersicum [tomato], Sterculiaceae, such as the genus Theobroma, for example the genus and species Theobroma cacao [cacao] or Theaceae, such as the genus Camellia, for example the genus and species Camellia sinensis [tea]. In particular preferred plants to be used as transgenic plants in accordance with the present invention are oil fruit crops which comprise large amounts of lipid compounds, such as peanut, oilseed rape, canola, sunflower, safflower, poppy, mustard, hemp, castor-oil plant, olive, sesame, Calendula, Punica, evening primrose, mullein, thistle, wild roses, hazelnut, almond, macadamia, avocado, bay, pumpkin/squash, linseed, soybean, pistachios, borage, trees (oil palm, coconut, walnut) or crops such as maize, wheat, rye, oats, triticale, rice, barley, cotton, cassava, pepper, Tagetes, Solanaceae plants such as potato, tobacco, eggplant and tomato, Vicia species, pea, alfalfa or bushy plants (coffee, cacao, tea), Salix species, and perennial grasses and fodder crops. Preferred plants according to the invention are oil crop plants such as peanut, oilseed rape, canola, sunflower, safflower, poppy, mustard, hemp, castor-oil plant, olive, Calendula, Punica, evening primrose, pumpkin/squash, linseed, soybean, borage, trees (oil palm, coconut). Especially preferred plants are plants such as sunflower, safflower, tobacco, mullein, sesame, cotton, pumpkin/squash, poppy, evening primrose, walnut, linseed, hemp, thistle or safflower. Very especially preferred plants are plants such as safflower, sunflower, poppy, evening primrose, walnut, linseed, or hemp.

Preferred mosses are Physcomitrella or Ceratodon. Preferred algae are Isochrysis, Mantoniella, Ostreococcus or Crypthecodinium, and algae/diatoms such as Phaeodactylum or Thraustochytrium. More preferably, said algae or mosses are selected from the group consisting of: Shewanella, Physcomitrella, Thraustochytrium, Nannochloropsis, Fusarium, Phytophthora, Ceratodon, Isochrysis, Aleurita, Muscarioides, Mortierella, Phaeodactylum, Cryphthecodinium, specifically from the genera and species Thallasiosira pseudonona, Euglena gracilis, Physcomitrella patens, Phytophtora infestans, Fusarium graminaeum, Cryptocodinium cohnii, Ceratodon purpureus, Isochrysis galbana, Aleurita farinosa, Thraustochytrium sp., Nannochloropsis oculata, Muscarioides viallii, Mortierella alpina, Phaeodactylum tricornutum or Caenorhabditis elegans or especially advantageously Phytophtora infestans and Cryptocodinium cohnii.

Transgenic plants may be obtained by transformation techniques as elsewhere in this specification. Preferably, transgenic plants can be obtained by T-DNA-mediated transformation. Such vector systems are, as a rule, characterized in that they contain at least the vir genes, which are required for the Agrobacterium-mediated transformation, and the sequences which delimit the T-DNA (T-DNA border). Suitable vectors are described elsewhere in the specification in detail.

Also encompassed are transgenic non-human animals comprising the vector or polynucleotide of the present invention. Preferred non-human transgenic animals envisaged by the present invention are fish, such as herring, salmon, sardine, redfish, eel, carp, trout, halibut, mackerel, zander or tuna.

It will be understood that in order to produce the LCPUFA according to the invention, the C16- or C18-fatty acids must first be desaturated by the enzymatic activity of a desaturase and subsequently be elongated by at least two carbon atoms via an elongase in the non-human transgenic organism. After one elongation cycle, this enzyme activity gives C18- or C20-fatty acids and after two or three elongation cycles C22- or C24-fatty acids. The activity of the desaturases and elongases used in the process according to the invention preferably leads to C18-, C20-, C22- and/or C24-fatty acids, advantageously with at least two double bonds in the fatty acid molecule, preferably with three, four or five double bonds, especially preferably to give C20- and/or C22-fatty acids with at least two double bonds in the fatty acid molecule, preferably with three, four or five double bonds in the molecule. After a first desaturation and the elongation have taken place, further desaturation steps such as, for example, one in the delta-5 position may take place. Products of the process according to the invention which are especially preferred are DGLA, ARA, EPA DPA and/or DHA, most preferably EPA and/or DHA. Desaturases and elongases which are required for this process may not always be present naturally in the organism. Accordingly, the present invention, preferably, envisages a transgenic non-human organism which in addition to the polynucleotide of the present invention comprises polynucleotides encoding such desaturases and/or elongases as required depending on the selected organism. Preferred desaturases and/or elongases which shall be present in the organism are at least one enzyme selected from the group consisting of: Δ-4-desaturase, Δ-5-desaturase, Δ-5-elongase, Δ-6-desaturase, Δ12-desaturase, Δ15-desaturase, ω3-desaturase and Δ-6-elongase. Especially prefered are the bifunctional d12d15-Desaturases d12d15Des(Ac) from Acanthamoeba castellanii (WO2007042510), d12d15Des(Cp) from Claviceps purpurea (WO2008006202) and d12d15Des(Lg)1 from Lottia gigantea (WO2009016202), the d12-Desaturases d12Des(Co) from Calendula officinalis (WO200185968), d12Des(Lb) from Laccaria bicolor (WO2009016202), d12Des(Mb) from Monosiga brevicollis (WO2009016202), d12Des(Mg) from Mycosphaerella graminicola (WO2009016202), d12Des(Nh) from Nectria haematococca (WO2009016202), d12Des(Ol) from Ostreococcus lucimarinus (WO2008040787), d12Des(Pb) from Phycomyces blakesleeanus (WO2009016202), d12Des(Ps) from Phytophthora sojae (WO2006100241) and d12Des(Tp) from Thalassiosira pseudonana (WO2006069710), the d15-Desaturases d15Des(Hr) from Helobdella robusta (WO2009016202), d15Des(Mc) from Microcoleus chthonoplastes (WO2009016202), d15Des(Mf) from Mycosphaerella fijiensis (WO2009016202), d15Des(Mg) from Mycosphaerella graminicola (WO2009016202) and d15Des(Nh)2 from Nectria haematococca (WO2009016202), the d4-Desaturases d4Des(Eg) from Euglena gracilis (WO2004090123), d4Des(Tc) from Thraustochytrium sp. (WO2002026946) and d4Des(Tp) from Thalassiosira pseudonana (WO2006069710), the d5-Desaturases d5Des(Ol)2 from Ostreococcus lucimarinus (WO2008040787), d5Des(Pp) from Physcomitrella patens (WO2004057001), d5Des(Pt) from Phaeodactylum tricornutum (WO2002057465), d5Des(Tc) from Thraustochytrium sp. (WO2002026946), d5Des(Tp) from Thalassiosira pseudonana (WO2006069710) and the d6-Desaturases d6Des(Cp) from Ceratodon purpureus (WO2000075341), d6Des(Ol) from Ostreococcus lucimarinus (WO2008040787), d6Des(Ot) from Ostreococcus tauri (WO2006069710), d6Des(Pf) from Primula farinosa (WO2003072784), d6Des(Pir)_BO from Pythium irregulare (WO2002026946), d6Des(Pir) from Pythium irregulare (WO2002026946), d6Des(Plu) from Primula luteola (WO2003072784), d6Des(Pp) from Physcomitrella patens (WO200102591), d6Des(Pt) from Phaeodactylum tricornutum (WO2002057465), d6Des(Pv) from Primula vialii (WO2003072784) and d6Des(Tp) from Thalassiosira pseudonana (WO2006069710), the d8-Desaturases d8Des(Ac) from Acanthamoeba castellanii (EP1790731), d8Des(Eg) from Euglena gracilis (WO200034439) and d8Des(Pm) from Perkinsus marinus (WO2007093776), the o3-Desaturases o3Des(Pi) from Phytophthora infestans (WO2005083053), o3Des(Pir) from Pythium irregulare (WO2008022963), o3Des(Pir)2 from Pythium irregulare (WO2008022963) and o3Des(Ps) from Phytophthora sojae (WO2006100241), the bifunctional d5d6-elongases d5d6Elo(Om)2 from Oncorhynchus mykiss (WO2005012316), d5d6Elo(Ta) from Thraustochytrium aureum (WO2005012316) and d5d6Elo(Tc) from Thraustochytrium sp. (WO2005012316), the d5-elongases d5Elo(At) from Arabidopsis thaliana (WO2005012316), d5Elo(At)2 from Arabidopsis thaliana (WO2005012316), d5Elo(Ci) from Ciona intestinalis (WO2005012316), d5Elo(Ol) from Ostreococcus lucimarinus (WO2008040787), d5Elo(Ot) from Ostreococcus tauri (WO2005012316), d5Elo(Tp) from Thalassiosira pseudonana (WO2005012316) and d5Elo(Xl) from Xenopus laevis (WO2005012316), the d6-elongases d6Elo(Ol) from Ostreococcus lucimarinus (WO2008040787), d6Elo(Ot) from Ostreococcus tauri (WO2005012316), d6Elo(Pi) from Phytophthora infestans (WO2003064638), d6Elo(Pir) from Pythium irregulare (WO2009016208), d6Elo(Pp) from Physcomitrella patens (WO2001059128), d6Elo(Ps) from Phytophthora sojae (WO2006100241), d6Elo(Ps)2 from Phytophthora sojae (WO2006100241), d6Elo(Ps)3 from Phytophthora sojae (WO2006100241), d6Elo(Pt) from Phaeodactylum tricornutum (WO2005012316), d6Elo(Tc) from Thraustochytrium sp. (WO2005012316) and d6Elo(Tp) from Thalassiosira pseudonana (WO2005012316), the d9-elongases d9Elo(Ig) from Isochrysis galbana (WO2002077213), d9Elo(Pm) from Perkinsus marinus (WO2007093776) and d9Elo(Ro) from Rhizopus oryzae (WO2009016208).

Furthermore, the present invention encompasses a method for the manufacture of polyunsaturated fatty acids comprising:

-   a) cultivating the host cell of the invention under conditions which     allow for the production of polyunsaturated fatty acids in said host     cell; and -   b) obtaining said polyunsaturated fatty acids from the said host     cell.

The term “polyunsaturated fatty acids (PUFA)” as used herein refers to fatty acids comprising at least two, preferably, three, four, five or six, double bonds. Moreover, it is to be understood that such fatty acids comprise, preferably from 18 to 24 carbon atoms in the fatty acid chain. More preferably, the term polyunsaturated fatty acids relates to long chain PUFA (LCPUFA) having from 20 to 24 carbon atoms in the fatty acid chain. Preferred unsaturated fatty acids in the sense of the present invention are selected from the group consisting of arachidonic acid (ARA) 20:4 (5,8,11,14), eicosapentaenoic acid (EPA) 20:5 (5,8,11,14,17), and docosahexaenoic acid (DHA) 22:6 (4,7,10,13,16,19) and, more preferably, from EPA and DHA. Thus, it will be understood that most preferably, the methods provided by the present invention relating to the manufacture of EPA or DHA. Moreover, also encompassed are the intermediates of LCPUFA which occur during synthesis starting from oleic acid 18:1 (9), preferably, linoleic acid 18:2 (9,12), alpha-linolenic acid 18:3 (9,12,15), gamma-linolenic acid 18:3 (6,9,12), stearidonic acid 18:4 (6,9,12,15), dihomo-gamma-linoleic acid 20:3 (8,11,14), eicosadienoic acid 20:2 (11,14), eicosatrienoic acid 20:3 (11,14,17), eicosatetraenoic acid 20:4 (8,11,14,17) and docospentaenoic acid (DPA) 22:5 (4,7,10,13,16).

The term “cultivating” as used herein refers maintaining and growing the host cells under culture conditions which allow the cells to produce the said polyunsaturated fatty acid, i.e. the PUFA and/or LCPUFA referred to above, preferably, as triglyceride esters. This implies that the polynucleotide of the present invention is expressed in the host cell so that the acyltransferase activity is present. Suitable culture conditions for cultivating the host cell are described in more detail below.

The term “obtaining” as used herein encompasses the provision of the cell culture including the host cells and the culture medium as well as the provision of purified or partially purified preparations thereof comprising the polyunsaturated fatty acids, preferably, as triglyceride esters. More preferably, the PUFA and LCPUFA are to be obtained as triglyceride esters, e.g., in form of an oil. More details on purification techniques can be found elsewhere herein below.

The host cells to be used in the method of the invention are grown or cultured in the manner with which the skilled artisan is familiar, depending on the host organism. Usually, host cells are grown in a liquid medium comprising a carbon source, usually in the form of sugars, a nitrogen source, usually in the form of organic nitrogen sources such as yeast extract or salts such as ammonium sulfate, trace elements such as salts of iron, manganese and magnesium and, if appropriate, vitamins, at temperatures of between 0° C. and 100° C., preferably between 10° C. and 60° C. under oxygen or anaerobic atmosphere depedent on the type of organism. The pH of the liquid medium can either be kept constant, that is to say regulated during the culturing period, or not. The cultures can be grown batchwise, semibatchwise or continuously. Nutrients can be provided at the beginning of the fermentation or administerd semicontinuously or continuously: The produced PUFA or LCPUFA can be isolated from the host cells as described above by processes known to the skilled artisan, e.g., by extraction, distillation, crystallization, if appropriate precipitation with salt, and/or chromatography. It might be required to disrupt the host cells prior to purification. To this end, the host cells can be disrupted beforehand. The culture medium to be used must suitably meet the requirements of the host cells in question. Descriptions of culture media for various microorganisms which can be used as host cells according to the present invention can be found in the textbook “Manual of Methods for General Bacteriology” of the American Society for Bacteriology (Washington D.C., USA, 1981). Culture media can also be obtained from various commercial suppliers. All media components are sterilized, either by heat or by filter sterilization. All media components may be present at the start of the cultivation or added continuously or batchwise, as desired. If the polynucleotide or vector of the invention which has been introduced in the host cell further comprises an expressible selection marker, such as an antibiotic resistance gene, it might be necessary to add a selection agent to the culture, such as an antibiotic in order to maintain the stability of the introduced polynucleotide. The culture is continued until formation of the desired product is at a maximum. This is normally achieved within 10 to 160 hours. The fermentation broths can be used directly or can be processed further. The biomass may, according to requirement, be removed completely or partially from the fermentation broth by separation methods such as, for example, centrifugation, filtration, decanting or a combination of these methods or be left completely in said broth. The fatty acid preparations obtained by the method of the invention, e.g., oils, comprising the desired PUFA or LCPUFA as triglyceride esters are also suitable as starting material for the chemical synthesis of further products of interest. For example, they can be used in combination with one another or alone for the preparation of pharmaceutical or cosmetic compositions, foodstuffs, or animal feeds. Chemically pure triglycerides comprising the desired PUFA or LCPUFA can also be manufactured by the methods described above. To this end, the fatty acid preparations are further purified by extraction, distillation, crystallization, chromatography or combinations of these methods. In order to release the fatty acid moieties from the triglycerides, hydrolysis may be also required. The said chemically pure triglycerides or free fatty acids are, in particular, suitable for applications in the food industry or for cosmetic and pharmacological compositions.

Moreover, the present invention relates to a method for the manufacture of polyunsaturated fatty acids comprising:

-   a) cultivating the non-human transgenic organism of the invention     under conditions which allow for the production of polyunsaturated     fatty acids in said host cell; and -   b) obtaining said polyunsaturated fatty acids from the said     non-human transgenic organism.

Further, it follows from the above that a method for the manufacture of an oil, lipid or fatty acid composition is also envisaged by the present invention comprising the steps of any one of the aforementioned methods and the further step of formulating PUFA or LCPUFA as oil, lipid or fatty acid composition. Preferably, said oil, lipid or fatty acid composition is to be used for feed, foodstuffs, cosmetics or pharmaceuticals. Accordingly, the formulation of the PUFA or LCPUFA shall be carried out according to the GMP standards for the individual envisaged products. For example, oil may be obtained from plant seeds by an oil mill. However, for product safety reasons, sterilization may be required under the applicable GMP standard. Similar standards will apply for lipid or fatty acid compositions to be applied in cosmetic or pharmaceutical compositions. All these measures for formulating oil, lipid or fatty acid compositions as products are comprised by the aforementioned manufacture.

The present invention also relates to oil comprising a polyunsaturated fatty acid or a polyunsaturated fatty acid composition obtainable by the aforementioned methods.

The term “oil” refers to a fatty acid mixture comprising unsaturated and/or saturated fatty acids which are esterified to triglycerides. Preferably, the triglycerides in the oil of the invention comprise PUFA or LCPUFA as referred to above. The amount of esterified PUFA and/or LCPUFA is, preferably, approximately 30%, a content of 50% is more preferred, a content of 60%, 70%, 80% or more is even more preferred. The oil may further comprise free fatty acids, preferably, the PUFA and LCPUFA referred to above. For the analysis, the fatty acid content can be, e.g., determined by GC analysis after converting the fatty acids into the methyl esters by transesterification. The content of the various fatty acids in the oil or fat can vary, in particular depending on the source. The oil, however, shall have a non-naturally occurring composition with respect to the PUFA and/or LCPUFA composition and content. It will be understood that such a unique oil composition and the unique esterification pattern of PUFA and LCPUFA in the triglycerides of the oil shall only be obtainable by applying the methods of the present invention specified above. Moreover, the oil of the invention may comprise other molecular species as well. Specifically, it may comprise minor impurities of the polynucleotide or vector of the invention. Such impurities, however, can be detected only by highly sensitive techniques such as PCR.

The contents of all references cited throughout this application are herewith incorporated by reference in general and with respect to their specific disclosure content referred to above.

This invention is further illustrated by the following figures and examples which should not be construed as limiting the scope of the invention.

FIGURES

FIG. 1: Cloning strategy employed for stepwise buildup of plant expression plasmids of the invention.

FIG. 2: Vector map of the bbc construct used for Arabidopsis transformation.

FIG. 3: GC chromatogram of fatty acids methyl esters of total fatty acids of Col-0, fae1 mutant and fae1 transformed with bbc. Total fatty acids were measured as described by Wu et al., 2005. The content of the different fatty is indicated in table 5.

FIG. 4: Total ion count of 26 acyl CoA ESI-MS/MS MRM pairs for Arabidopsis (A) Col-0 and (B) fae1 harbouring EPA biosynthesis pathway. Maturing Arabidopsis seeds were harvested 18 days after flowering. Acyl-CoA was extracted according to Larson et al (2001) and LC conditions after Han et al. (2010).

FIG. 5: Identification of Eicosapentaenoic and Arachidonic-CoA's in the acyl CoA pool of Arabidopsis Col-0 and EPA producing plants. MRM chromatograms of co-eluting acyl-CoA of interest in (A) wild type and (C) fae1 harbouring EPA biosynthetic pathway with recorded reactions shown for each transition, isotopic peaks (IP) of homologous long chain acyl CoA are shown. (B) Characteristic fragmentation of the protonated acyl-CoA by neutral loss of 507 to give the protonated acyl pantetheine group.

FIG. 6: LPCAT activity assay.

A yeast mutant lacking LPEAT and LPCAT activity (due to knockout of the gene YOR175c) was transformed with the empty vector pYES2.1 (lane marked “−”) and with pYES2.1 harboring the cDNA of pLPAAT_c6316(No) (lane 1 and 2, SEQ-ID: 13). Microsomal isolations of these transformants and the wildtype yeast strain BY4742 (lane marked “+”) containing 5 μg protein where incubated with alpha-linolenic acid-CoA and [¹⁴C]-18:1-lysophosphatidylcholine (LPC). Thin layer chromatography was performed to separate lipid classes. Like for wildtype yeast (lane marked “+”), phosphatidylcholine (PC) is observed for both yeast clones shown in lane 1 and 2, indicating the gene pLPAAT_c6316(No) has LPCAT activity and complements the missing LPCAT activity of the knockout strain.

FIG. 7: LPAAT activity assay.

A yeast mutant lacking LPAAT activity (due to knockout of the gene YDL052c) was transformed with the empty vector pYES2.1 (lane marked “−”) and with pYES2.1 harboring the cDNA of pLPAAT_c6316(No) (lane 1 and 2, SEQ-ID: 13). Microsomal isolations of these transformants and the wildtype yeast strain BY4742 (lane marked “+”) containing 5 μg protein where incubated with alpha-linolenic acid-CoA and [¹⁴C]-18:1-lysophosphatidic acid (LPA). Thin layer chromatography was performed to separate lipid classes. Like for wildtype yeast (lane marked “+”), phosphatidic acid (PA) is observed for both yeast clones shown in lane 1 and 2, indicating the gene pLPAAT_c6316(No) has LPAAT activity and complements the missing LPAAT activity of the knockout strain.

FIG. 8: DGAT activity assay.

A yeast mutant lacking the capability to synthesis TAG (due to knockout of the four genes YCR048W, YNR019W, YOR245C and YNR008W) was transformed with the empty vector pYES2.1 (lane marked “−”) and with pYES2.1 harboring the cDNA of pDGAT2-c19425mod(Ta) (SEQ-ID 52, lane 1 and 2), pDGAT2_c4648(No) (SEQ-ID 34, lane 5 and 6), pDGAT2_c48271(No) (SEQ-ID 102, lane 7 and 8), BnDGAT1 (SEQ-ID 107, lane 9 and 10), AtDGAT1 (SEQ-ID 105, lane 11 and 12), pDGAT2_c699(No) (SEQ-ID 19, lane 13 and 14) and pDGAT2_c2959(No) (SEQ-ID 25, lane 15). Microsomal isolations of these transformants and the wildtype yeast strain G175 (lane marked “+”) where incubated with ¹⁴C-labeled oleic acid and diacylglyerole (DAG). Thin layer chromatography was performed to separate lipid classes. Like for wildtype yeast (lane marked “+”), triacylglycerole (TAG) is observed in lane 1, 2, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15, indicating pDGAT2-c19425mod(Ta), pDGAT2_c4648(No), pDGAT2_c48271(No), BnDGAT1, AtDGAT1, pDGAT2_c699(No) and pDGAT2_c2959(No) encode polypeptides having DGAT activity and complement the missing TAG-synthesis capability of the knockout.

FIG. 9: Substrate specificity of AtDGAT1 and BnDGAT1. The specific activity of the enzymes AtDGAT1 and BnDGAT1 using the substrates indicated at the x-axis is given as the amount (in nmol) of substrate consumed in one minute per mg total protein and was determined as described in example 10.

FIG. 10: Substrate specificity of pDGAT2-c19425(Ta) compared to AtDGAT1 and BnDGAT1. The specific activity of the enzymes pDGAT2-c19425(Ta), AtDGAT1 and BnDGAT1 using the substrates indicated at the x-axis is given as the amount (in nmol) of substrate consumed in one minute per mg total protein and was determined as described in example 10.

FIG. 11: Substrate specificity of pDGAT2_c699(No) and pDGAT2_c4648(No) compared to AtDGAT1 and BnDGAT1. The specific activity of the enzymes pDGAT2_c699(No) and pDGAT2_c4648(No), AtDGAT1 and BnDGAT1 using the substrates indicated at the x-axis is given as the amount (in nmol) of substrate consumed in one minute per mg total protein and was determined as described in example 10.

EXAMPLES Example 1: General Cloning Methods

Cloning methods as e.g. use of restriction endonucleases to cut double stranded DNA at specific sites, agarose gel electrophoreses, purification of DNA fragments, transfer of nucleic acids onto nitrocellulose and nylon membranes, joining of DNA-fragments, transformation of E. coli cells and culture of bacteria where performed as described in Sambrook et al. (1989) (Cold Spring Harbor Laboratory Press: ISBN 0-87965-309-6).

Example 2: Sequence Analysis of Recombinant DNA

Sequencing of recombinant DNA-molecules was performed using a laser-fluorescence DNA sequencer (Applied Biosystems Inc, USA) employing the sanger method (Sanger et al. (1977) Proc. Natl. Acad. Sci. USA 74, 5463-5467). Expression constructs harboring fragments obtained by polymerase chain reactions were subjected to sequencing to confirm the correctness of expression cassettes consisting of promoter, nucleic acid molecule to be expressed and terminator to avoid mutations that might result from handling of the DNA during cloning, e.g. due to incorrect primers, mutations from exposure to UV-light or errors of polymerases.

Example 3: Cloning of Yeast Expression Construct Via Homologous Recombination

The open reading frame listed in SEQ ID NOs: 52, 1, 4, 7, 10, 13, 16, 19, 22, 25, 28, 31, 34, 37, 40, 43, 46, 49, 55, 102, 105 and 107 encoding polypeptides with the amino acid sequence SEQ ID NOs: 53, 2, 5, 8, 11, 14, 17, 20, 23, 26, 29, 32, 35, 38, 41, 44, 47, 50, 56,103, 106 and 108 that have acyltransferase activity can amplified using the primer listed in table 2 in a polymerase chain reaction. By doing so, the open reading frame is 5′ fused to about 60 nucleotides of the 3′ end of the GAL1 promotor sequence with simultaneous introduction of and Asc I and/or Nco I restriction site between the fusion site and 3′ fused to about 60 nucleotides of the 5′ end of the CYC1 terminator sequence with simultaneous introduction of and Pac I restriction site. To integrate these fragments into pYES2.1 TOPO downstream of the galactose inducible GAL1 Promotor via homologous recombination, the vector pYES2.1 (Invitrogen) can be digested using the restriction endonucleases Pvu II and Xba I, and Saccharomyces cerevisea can be transformed with 5 to 20 ng of linearized pYES2.1 TOPO vector and 20 to 100 ng PCR product per 50 μl competent cells using the transformation method described by Schiestl et al. (Schiestl et al. (1989) Curr. Genet. 16(5-6), pp. 339-346), to obtain pYES-pLPLAT_c1216(No), pYES-pLPLAT_c3052(No), pYES-pLPEAT-c7109(Ta), pYES-pLPAAT_c2283(No), pYES-pLPAAT_c6316(No), pYES-pDGAT2_Irc24907(No), pYES-pDGAT2_c699(No), pYES-pDGAT2_c1910(No), pYES-pDGAT2_c2959(No), pYES-pDGAT2_c4857(No), pYES-pDGAT1_c21701(No), pYES-pDGAT2_c4648(No), pYES-pDGAT2_c1660(No), pYES-pDGAT2_c29432(No), pYES-pDGAT2_c1052(No), pYES-pDGAT2-c18182(Ta), pYES-pDGAT2-c5568(Ta), pYES-pDGAT2-c19425(Ta), pYES-pDGAT2_c48271(No), AtDGAT1, BnDGAT1 and pYES-pGPAT_c813(No) in various wildtype yeasts and yeast mutants. Positive transformants can be selected based on the complementation of the URA auxotrophy of the chosen S. cerevisia strain. To validate the correctness of the expression construct harbored by a particular yeast clone, plasmids can be isolated as described in Current Protocols in Molecular Biology (Hoffmann, Curr. Protoc. Mol. Biol. 2001 May; Chapter 13:Unit13.11), transformed into E. coli for amplification and subjected to sequencing of the expression cassette as described in example 2. For later cloning into plant expression plasmids, the introduced restrictions site for Asc I and/or Nco I in combination with Pac I can be used.

TABLE 2 Primer sequences for cloning acyltransferase-polynucleotides of the invention for yeast expression Gene-Name Primer SEQ-ID pLPLAT_c1216(No) Forward:  46 ataaaagtatcaacaaaaaattgttaatatacctctatactttaacgt caaggagaaaaaaccccggatcggcgcgccaccatggacaa ggcactggcaccgtt Reverse:  47 aactataaaaaaataaatagggacctagacttcaggttgtctaact ccttccttttcggttagagcggatttaattaactaaactttcttccttccc tcta pLPLAT_c3052(No) Forward:  48 ataaaagtatcaacaaaaaattgttaatatacctctatactttaacgt caaggagaaaaaaccccggatcggcgcgccaccatgaccacg actgtcatctctag Reverse:  49 aactataaaaaaataaatagggacctagacttcaggttgtctaact ccttccttttcggttagagcggatttaattaatcaaagcctcccgcac aacgagc pLPEAT-c7109(Ta) Forward:  50 ataaaagtatcaacaaaaaattgttaatatacctctatactttaacgt caaggagaaaaaaccccggatcggcgcgccaccatggaggg catcgagtcgatagt Reverse:  51 aactataaaaaaataaatagggacctagacttcaggttgtctaact ccttccttttcggttagagcggatttaattaactataaggcttctcccg gcgcgg pLPAAT_c2283(No) Forward:  52 ataaaagtatcaacaaaaaattgttaatatacctctatactttaacgt caaggagaaaaaaccccggatcggcgcgccaccatgaagac gcccacgagcctggc Reverse:  53 aactataaaaaaataaatagggacctagacttcaggttgtctaact ccttccttttcggttagagcggatttaattaattaagctctcgaatcgtc cttct pLPAAT_c6316(No) Forward:  54 ataaaagtatcaacaaaaaattgttaatatacctctatactttaacgt caaggagaaaaaaccccggatcggcgcgccaccatggtcagg aggaagatggacgt Reverse:  55 aactataaaaaaataaatagggacctagacttcaggttgtctaact ccttccttttcggttagagcggatttaattaatcacgacgccggcgc cttgcagt pDGAT2_lrc24907(No) Forward:  56 ataaaagtatcaacaaaaaattgttaatatacctctatactttaacgt caaggagaaaaaaccccggatcggcgcgccaccatggcaccc tccccaccggcccc  57 Reverse: aactataaaaaaataaatagggacctagacttcaggttgtctaact ccttccttttcggttagagcggatttaattaatcatttgaccactaaggt ggcct pDGAT2_c699(No) Forward:  58 ataaaagtatcaacaaaaaattgttaatatacctctatactttaacgt caaggagaaaaaaccccggatcggcgcgccaccatgggtctat ttggcagcgggat Reverse:  59 aactataaaaaaataaatagggacctagacttcaggttgtctaact ccttccttttcggttagagcggatttaattaactaaaagaaattcaac gtccgat pDGAT2_c1910(No) Forward:  60 ataaaagtatcaacaaaaaattgttaatatacctctatactttaacgt caaggagaaaaaaccccggatcggcgcgccaccatgttgagta  tccccgagtcgtc Reverse:  61 aactataaaaaaataaatagggacctagacttcaggttgtctaact ccttccttttcggttagagcggatttaattaactaaaagaaatccagc tccctgt pDGAT2_c2959(No) Forward:  62 ataaaagtatcaacaaaaaattgttaatatacctctatactttaacgt caaggagaaaaaaccccggatcggcgcgccaccatgacgccg caagccgatatcac Reverse:  63 aactataaaaaaataaatagggacctagacttcaggttgtctaact ccttccttttcggttagagcggatttaattaattactcaatggacaacg ggcgcg pDGAT2_c4857(No) Forward:  64 ataaaagtatcaacaaaaaattgttaatatacctctatactttaacgt caaggagaaaaaaccccggatcggcgcgccaccatggcttacc tcttccgtcgtcg Reverse:  65 aactataaaaaaataaatagggacctagacttcaggttgtctaact ccttccttttcggttagagcggatttaattaattaggcgatcgcaatg aactcct pDGAT1_c21701(No) Forward:  66 ataaaagtatcaacaaaaaattgttaatatacctctatactttaacgt caaggagaaaaaaccccggatcggcgcgccaccatgccttttg gacgggctgcatc Reverse:  67 aactataaaaaaataaatagggacctagacttcaggttgtctaact ccttccttttcggttagagcggatttaattaatcacccgaaaatatcct ccttct pDGAT2_c4648(No) Forward:  68 ataaaagtatcaacaaaaaattgttaatatacctctatactttaacgt caaggagaaaaaaccccggatcggcgcgccaccatggccaa ggctaacttcccgcc Reverse:  69 aactataaaaaaataaatagggacctagacttcaggttgtctaact ccttccttttcggttagagcggatttaattaatcactttataagcagctt cttgt pDGAT2_c1660(No) Forward:  70 ataaaagtatcaacaaaaaattgttaatatacctctatactttaacgt caaggagaaaaaaccccggatcggcgcgccaccatgttgttgc agggattaagctg Reverse:  71 aactataaaaaaataaatagggacctagacttcaggttgtctaact ccttccttttcggttagagcggatttaattaatcacaacaggaccaat ttatgat pDGAT2_c29432(No) Forward:  72 ataaaagtatcaacaaaaaattgttaatatacctctatactttaacgt caaggagaaaaaaccccggatcggcgcgccaccatgttgatgg cgccgtcgcggcg Reverse:  73 aactataaaaaaataaatagggacctagacttcaggttgtctaact ccttccttttcggttagagcggatttaattaatcagacgatgcgaagc gtcttgt pDGAT2_c1052(No) Forward:  74 ataaaagtatcaacaaaaaattgttaatatacctctatactttaacgt caaggagaaaaaaccccggatcggcgcgccaccatgggcgct accactgcgaccca Reverse:  75 aactataaaaaaataaatagggacctagacttcaggttgtctaact ccttccttttcggttagagcggatttaattaatcacgacttcggacagt ccaaaa pDGAT2-c18182(Ta) Forward:  76 ataaaagtatcaacaaaaaattgttaatatacctctatactttaacgt caaggagaaaaaaccccggatcggcgcgccaccatgtcgttcg ttgagcacagcgc Reverse:  77 aactataaaaaaataaatagggacctagacttcaggttgtctaact ccttccttttcggttagagcggatttaattaactacacaaatcgcatc gtcttgt pDGAT2-c5568(Ta) Forward:  78 ataaaagtatcaacaaaaaattgttaatatacctctatactttaacgt caaggagaaaaaaccccggatcggcgcgccaccatggtcttcct ctgccttcccta Reverse:  79 aactataaaaaaataaatagggacctagacttcaggttgtctaact ccttccttttcggttagagcggatttaattaactacgagtccagccac ttgatgc pDGAT2-c19425(Ta) Forward:  80 ataaaagtatcaacaaaaaattgttaatatacctctatactttaacgt caaggagaaaaaaccccggatcggcgcgccaccatgtttcttcg catcgaacggga Reverse:  81 aactataaaaaaataaatagggacctagacttcaggttgtctaact ccttccttttcggttagagcggatttaattaactaaccctcggtgtaca gcgccg pGPAT_c813(No) Forward:  82 ataaaagtatcaacaaaaaattgttaatatacctctatactttaacgt caaggagaaaaaaccccggatcggcgcgccaccatgccatcc cgcagcaccattga Reverse:  83 aactataaaaaaataaatagggacctagacttcaggttgtctaact ccttccttttcggttagagcggatttaattaatcagacaagctcctctt ccccct pDGAT2_c48271(No) Forward: 109 ataaaagtatcaacaaaaaattgttaatatacctctatactttaacgt caaggagaaaaaaccccggatcggcgcgccaccatggccgcc atctcaccgcgcaa Reverse: 110 aactataaaaaaataaatagggacctagacttcaggttgtctaact ccttccttttcggttagagcggatttaattaactaccacacctccaact tcgccc AtDGAT1 Forward: 111 ataaaagtatcaacaaaaaattgttaatatacctctatactttaacgt caaggagaaaaaaccccggatcggcgcgccaccatggcgattt tggattctgctgg Reverse: 112 aactataaaaaaataaatagggacctagacttcaggttgtctaact ccttccttttcggttagagcggatttaattaatcatgacatcgatcctttt cggt BnDGAT1 Forward: 113 ataaaagtatcaacaaaaaattgttaatatacctctatactttaacgt caaggagaaaaaaccccggatcggcgcgccaccatggagattt tggattctggagg Reverse: 114 aactataaaaaaataaatagggacctagacttcaggttgtctaact ccttccttttcggttagagcggatttaattaactatgacatctttcctttg cggt

TABLE 3 Coding polynucleotide sequences, amino acid sequences encoded thereby and expressed sequences (mRNA) of the acyltransferases of the invention SEQ- SEQ- ORF SEQ- Amino ID mRNA ID Gene name Organism in bp ID No. acids No. in bp No. pLPLAT_c1216(No) Nannochloropsis 1485 1 494 2 1908 3 oculata pLPLAT_c3052(No) Nannochloropsis 1776 4 591 5 2247 6 oculata pLPEAT-c7109(Ta) Thraustochytrium 1134 7 377 8 1288 9 aureum pLPAAT_c2283(No) Nannochloropsis 1284 10 427 11 1826 12 oculata pLPAAT_c6316(No) Nannochloropsis 1395 13 464 14 1771 15 oculata pDGAT2_Irc24907 Nannochloropsis 1026 16 341 17 1100 18 (No) oculata pDGAT2_c699(No) Nannochloropsis 1206 19 401 20 1772 21 oculata pDGAT2_c1910(No) Nannochloropsis 1173 22 390 23 1239 24 oculata pDGAT2_c2959(No) Nannochloropsis 1089 25 362 26 1609 27 oculata pDGAT2_c4857(No) Nannochloropsis 1464 28 487 29 1682 30 oculata pDGAT1_c21701 Nannochloropsis 1539 31 512 32 1904 33 (No) oculata pDGAT2_c4648(No) Nannochloropsis 1083 34 360 35 1362 36 oculata pDGAT2_c1660(No) Nannochloropsis 1695 37 564 38 2074 39 oculata pDGAT2_c29432 Nannochloropsis 1029 40 342 41 1585 42 (No) oculata pDGAT2_c1052(No) Nannochloropsis 1251 43 416 44 1923 45 oculata pDGAT2- Thraustochytrium 930 46 309 47 1134 48 c18182(Ta) aureum pDGAT2- Thraustochytrium 1179 49 392 50 1303 51 c5568(Ta) aureum pDGAT2- Thraustochytrium 1389 52 462 53 1547 54 c19425(Ta) aureum pGPAT_c813(No) Nannochloropsis 1977 55 658 56 2460 57 oculata pDGAT2_c48271 Nannochloropsis 960 102 319 103 1265 104 (No) oculata

Example 4: Assembly of Genes Required for PUFA Synthesis within a T-Plasmid

For synthesis of EPA in Arabidopsis seeds, the set of genes encoding the proteins of the metabolic EPA pathway (table 4) was combined with expression elements (promoter, terminators) and transferred into binary t-plasmids that were used for agrobacteria mediated transformation of plants as described in example 5. To this end, the general cloning strategy depicted in FIG. 1 was employed: Genes listed in table 4 were PCR-amplified using Phusion™ High-Fidelity DNA Polymerase (NEB, Frankfurt, Germany) according to the manufactures instructions from cDNA using primer introducing a Nco I and/or Asc I restriction site at the 5′ terminus, and a Pac I restriction site at the 3′ terminus (FIG. 1B). To obtain the final expression modules, PCR-amplified genes were cloned between promoter and terminator via Nco I and/or Pac I restriction sites (FIG. 1C). Up to three of those expression modules were combined as desired to expression cassettes harbored by either one of pENTR/A, pENTR/B or pENTR/C (FIG. 1D). Finally, the Multisite Gateway™ System (Invitrogen) was used to combine three expression cassette harbored by pENTR/A, pENTR/B and pENTR/C (FIG. 1E) to obtain the final binary T-plasmids bbc (SEQ-ID 101, FIG. 2).

TABLE 4 Genes of the bbc construct for synthesis of EPA (20:5n-3) in Arabidopsis seeds. The elements controlling the expression of the respective genes are as well indicated. Name Source Organism Activity SEQ-ID Promoter Terminator d12Des(Ps) Phytophtora sojae d-12 Desaturase 96 p-BnNapin t-E9 d6Des(Ot) Ostreococcus tauri d-6 Desaturase 97 p-SBP t-CatpA d5Des(Tc) Traustochytrium ssp. d-5 Desaturase 98 p-LuCnl t-AgroOCS d6Elo(Pp) Physcomitrella patens d-6 Elongase 99 p-VfUSP t-CaMV35S o-3Des(Pi) Phytophthora o-3 Desaturase 100 p-Napin t-E9 infestans

Example 5: Plant Transformation

The resulting binary vector bbc harboring the genes reconstituting EPA biosynthesis pathway were transformed into Agrobacterium tumefaciens (Hofgen and Willmitzer (1988) Nucl. Acids Res. 16: 9877). The transformation of A. thaliana was accomplished by means of the floral-dip method (Clough and Bent (1998) Plant Journal 16: 735-743), this method is known to the skilled person. Wild-type Arabidopsis seeds contain considerable amounts of eicosenoic acid (20:1) (Table 5). Biosynthesis of 20:1 competes for the substrates of the PUFA biosynthesis pathway. This competition was circumvented by transforming bbc into the Arabidopsis fae1 mutant (James et al., (1995) The Plant Cell 7:309-319).

Example 6: Quantification of Metabolic Fatty Acyl-CoAs in Wild-Type and EPA Producing Arabidopsis Seeds

The selected transgenic Arabidopsis plants from example 3 were analyzed in respect to PUFA content in seeds. Seeds from wild-type, fae1 mutant and transgenics harboring the bbc construct were harvested 18 days after flowering. Total fatty acid, representing the fatty acids esterified to CoA, on lipids and as triacyl-glycerides were extracted and analyzed by gas chromatography as described in Wu et al., (2005) Nature Biotechnology 23(8): 1013-1017. In seeds of fae1 transformed with bbc the EPA accumulation was 12.2%, the seeds contained small amounts of intermediate or side products: ARA (3.2%), SDA (0.8%), GLA (2.6%) which were not present in wild-type or fae1 (FIG. 3, Table 5).

TABLE 5 Content of fatty acids in seeds of wild-type (Col-0), fae1 mutant and fae1 transformed with bbc construct Fatty acid Common name of FA Col-0 fae1 bbc fae1 16:0 Palmitic acid 6.2 8.8 6.8 18:0 Stearic acid 3.1 4.1 5.3 18:1 Oleic acid 16.3 27.5 18.9 18:2 Linoleic acid 28.2 39.0 30.8 18:3n6 Gamma-Linolenic acid 0.0 0.0 2.6 18:3n3 Alpha-Linoleic acid 15.6 18.4 11.9 18:4n3 Stearidonic acid 0.0 0.0 0.8 20:1 Eicosenoic acid 22.8 0.4 0.3 20:4n6 Arachidonic acid 0.0 0.0 3.2 20:5n3 Eicosapentaenoic acid 0.0 0.0 12.2 Others 7.8 1.8 7.2

For PUFA biosynthesis the acyl-moiety has to be shuffled between different metabolic pools. For example, the elongation of the acyl chain by two carbon atoms occurs specifically on acyl-CoA (Zank et al., (2002) The Plant Journal 318(3):255-268. The efficiency of the transfer of the acyl-residue between the metabolic pools may represent a bottleneck for PUFA production in plants. Therefore the accumulation of EPA or intermediates of EPA biosynthesis as CoA species was analyzed by LC/MS². As a control CoA pool of wild-type seeds were as well analyzed. The Acyl-CoA metabolites were extracted from the seed tissue according to Larson and Graham, 2001. LC/MS² was applied as described by Magnes et al., 2005. Briefly, CoA were separeted with high resolution by reversed-phase high performance liquid chromatography (HPLC) with a ammonium hydroxide and acetonitrile gradient. The acyl-CoA species were identified and quantified by multireaction monitoring using triple quadrupole mass spectrometry. Only a few methods using mass spectrometry for characterization of long chain acyl-CoA have been published, the majority of which employ negative ionisation mode showing abundant ions. In contrast, positive ionisation has only one abundant ion [M-H]+, furthermore the predominant ion in MS² spectra is the fatty acyl-pantetheine fragment (m/z 507—FIG. 5B), characteristic of CoA-activated substances. In choosing the acyl-pantetheine of interest in multireaction monitoring mode (MRM) a very sensitive, selective and reproducible method was established. CoA-activated substances can be monitored by scanning for the neutral loss of phosphoadenosine diphosphate. Generally for reliable analysis, all interfering peaks must be chromatographically separated; in the case of EPA and ARA this is not possible (FIG. 4B). However through the use of MRM, incorporating very short dwell times (15 ms), it is possible to follow the individual chromatograms of acyl-CoA of interest and demonstrate the presence of EPA and ARA in the acyl CoA pool (FIG. 5C). According to internal standards the eicosapentaenoyl-CoA was in the range of . . . % of the total Co-A pool.

In conclusion these results show that PUFA accumulate in the metabolic CoA pool and are not transferred to DAG to be released as TAG into the seed oil. Such a bottleneck may be overcome by the co-expression of an acyltransferase from table 3, having the appropriate substrate specificity. The application of suitable acyltransferase may increase the flux of fatty acid between the metabolic pools and increase the PUFA biosynthesis rate.

Example 7: Activity Assays Using Yeast Extracts

To characterize the functions of the acyltransferase polypeptides of the invention, yeast mutants can be employed that are defective in certain acyltransferase activities. For example, the yeast mutant Y13749 (Genotype: BY4742; Mat alpha; his3Δ1; leu2Δ0; lys2Δ0; ura3Δ0; YDL052c::kanMX4) lacking LPAAT activity can be transformed with expression constructs harboring candidate polypeptides to check for restoration (complementation) of LPAAT activity, the yeast mutant Y12431 (genotype BY4742; Mat alpha; his3Δ1; leu2Δ0; lys2Δ0; ura3Δ0; YOR175c::kanMX4) lacking LPLAT activity can be transformed with expression constructs harboring candidate polypeptides to check for restoration (complementation) of LPLAT activity, the yeast mutant H1246 (genotype MATa leu2-3, 112 trp1-1 can1-100 ura3-1 ade2-1 his3-11, 15 YOR245::KanMX4 YNR008W::TRP1 YCR048W::HIS3 YNR019W::LEU2) lacking the ability to synthesize triacylglycerole can be transformed with expression constructs harboring candidate polypeptides to check for restoration (complementation) of the ability to synthesis triacylglycerole. The yeast mutants can for example harbor the expression constructs listed in example 3 employing the transformation method described in example 3.

For LPAAT activity assay, clones of the yeast mutant Y13749 harboring pYES-pLPAAT_c6316(No) can be grown at 28° C. in 10 ml selective media (SC-URA) with 2% raffinose as carbon source over night. The next day, expression of the acyltransferase polypeptide can be induced by transferring the cells to fresh media containing 2% galactose, for example by inoculating 100 ml of fresh culture to an optical density (measure at 600 nm) of OD₆₀₀=0.1. Cells are harvested after 24 h incubation at 28° C. by centrifugation at 3000×g for 5 min and resuspended in 1 ml resuspention buffer (25 mM Tris/HCL pH 7.6) and disrupted using acid washed zirconium bead (200 μm average diameter) in a mill (Retsch, Germany) by three minutes agitation at 300 rpm. The supernatant is transferred to a fresh tube and centrifuged at 3000×g for 5 min. The obtained supernatant is the crude extract. Protein content is measured according to Bradford (Bradford, M. M. (1976), Anal. Biochem. Bd. 72, pp. 248-254) with bovine serum albumin as standard. Assay mixtures contain 1 to 50 μg of protein, 10 μl of 100 nM [¹⁴C]-18:1-LPA (giving about 2000 dpm/nmol), 10 μl of 50 nM 18:1-CoA or 50 nM 18:3n-3-CoA in assay buffer (25 mM Tris/HCL pH 7.6, 0.5 mg/ml BSA) to give a total volume of 100 μl. Samples are incubated for 10 min at 30° C. The assays are terminated by extraction of the lipids into chloroform according to Blight and Dyer (Bligh, E. G. and Dyer, W. J. (1959), Can. J. Biochem. Physiol. 37, pp. 911-917). Lipids are separated on thin layer chromatography (TLC) silica 60 plates (Merck) using chloroform/methanol/acetic acid/water (90:15:10:3), and autoradiographic pictures are taken using an instant imager (Packard). It can be seen by the formation of phosphatidic acid (PA) in FIG. 7, that pLPAAT_c6316(No) (SEQ-ID 13, lane 1 and 2) encodes a polypetide having LPAAT activity.

For LPCAT and LPEAT activity assay, clones of the yeast mutant Y12431 harboring pYES-pLPAAT_c6316(No) can be grown at 28° C. in 10 ml selective media (SC-URA) with 2% raffinose as carbon source over night. The next day, expression of the acyltransferase polypeptide can be induced by transferring the cells to fresh media containing 2% galactose, for example by inoculating 100 ml of fresh culture to an optical density (measure at 600 nm) of OD₆₀₀=0.1. Cells are harvested after 24 h incubation at 28° C. by centrifugation at 3000×g for 5 min and resuspended in 1 ml resuspention buffer (25 mM Tris/HCL pH 7.6) and disrupted using acid washed zirconium bead (200 μm average diameter) in a mill (Retsch, Germany) by three minutes agitation at 300 rpm. The supernatant is transferred to a fresh tube and centrifuged at 3000×g for 5 min. The obtained supernatant is the crude extract. Protein content is measured according to Bradford (Bradford, M. M. (1976), Anal. Biochem. Bd. 72, pp. 248-254) with bovine serum albumin as standard. Assay mixtures contain either 10 μl 100 nM [¹⁴C]-LPC (LPCAT activity assay) or 10 μl 100 nM [¹⁴C]-LPE (LPEAT activity assay), 1 to 50 μg of protein, 10 μl of 50 nM 18:1-CoA or 50 nM 18:3n-3-CoA in assay buffer (25 mM Tris/HCL pH 7.6, 0.5 mg/ml BSA) to give a total volume of 100 μl. Samples are incubated for 10 min at 30° C. The assays are terminated by extraction of the lipids into chloroform according to Blight and Dyer (Bligh, E. G. and Dyer, W. J. (1959), Can. J. Biochem. Physiol. 37, pp. 911-917). Lipids are separated on thin layer chromatography (TLC) silica 60 plates (Merck) using chloroform/methanol/acetic acid/water (90:15:10:3), and autoradiographic pictures are taken using an instant imager (Packard). It can be seen by the formation of phosphatidylethanolamine (PC) in FIG. 6, that pLPAAT_c6316(No) (SEQ-ID 13, lane 1 and 2) encodes a polypeptide having LPCAT activity.

For DGAT activity assay, clones of the yeast mutant H1246 harboring either one of pYES-pDGAT2_c699(No), pYES-pDGAT2_c2959(No), pYES-pDGAT2_c4648(No), pYES-pDGAT2_c48271(No), pYES-pDGAT2-c19425(Ta), pYES-AtDGAT1, or pYES-BnDGAT1 can be grown at 28° C. in 10 ml selective media (SC-URA) with 2% raffinose as carbon source over night. The next day, expression of the acyltransferase polypeptides can be induced by transferring the cells to fresh media containing 2% galactose, for example by inoculating 100 ml of fresh culture to an optical density (measure at 600 nm) of OD₆₀₀=0.1. Activity as indicated by the formation of TAG (as indicated, the mutant H1246 is unable to synthesize TAG) can be measured either by relying on yeast-endogenous substrate-DAG, or by providing substrate in an in vitro assay.

For the former type of assay, cells are harvested after reaching stationary phase during incubation at 28° C. by centrifugation at 3000×g for 5 min and resuspended in 2 ml resuspention buffer (phosphate buffered saline (PBS) pH 7.4, see Sambrook et al., “Molecular Cloning”, Cold Spring Harbor Laboratory, 1989). The equivalent of 200 mg cell pellet is taken, the volume adjusted to 210 μl using PBS and 790 μl of methanol:chloroform (2:1) are added. Cells are disrupted using acid washed zirconium bead (200 μm average diameter) in a mill (Retsch, Germany) by three minutes agitation at 300 rpm and lipids are extracted according to Blight and Dyer (Bligh, E. G. and Dyer, W. J. (1959), Can. J. Biochem. Physiol. 37, pp. 911-917). The in vitro assay is the preferred way of testing for DGAT activity, when activity is known or expected to be week when relying on endogenous substrate. Instead, both the type and concentration of the DAG acceptor molecule, as well as the type and concentration of the fatty acid-CoA can be controlled. To do so, cells are harvested after 24 h incubation at 28° C. by centrifugation at 3000×g for 5 min and resuspended in 1 ml resuspention buffer (25 mM Tris/HCL pH 7.6) and disrupted using acid washed zirconium bead (200 μm average diameter) in a mill (Retsch, Germany) by three minutes agitation at 300 rpm. The supernatant is transferred to a fresh tube and centrifuged at 3000×g for 5 min. The obtained supernatant is the crude extract. Protein content is measured according to Bradford (Bradford, M. M. (1976), Anal. Biochem. Bd. 72, pp. 248-254) with bovine serum albumin as standard. Assay mixtures contain 10 μl 50 nM [¹⁴C]-6:0-DAG (giving about 3000 dpm/nmol), 50 μg of microsomal protein (the amount can be adjusted to stay within linear conditions without substrate limitation), 10 μl of 50 nM 18:3n-3-CoA or 50 nM 22:6n-3-CoA in assay buffer (50 mM Hepes buffer pH 7.2, 1 mg/ml BSA) to give a total volume of 100 μl. Samples are incubated for 10 min at 30° C.

In either case—in vivo or in vitro assay—lipids are separated on thin layer chromatography (TLC) silica 60 plates (Merck) using hexane:diethylether:acetic acid (70:30:1), and stained in iodine vapor. It can be seen by the formation of triacylglycerole (TAG) using the in vitro assay-conditions in FIG. 8, that pDGAT2-c19425mod(Ta) (SEQ-ID 52, lane 1 and 2), pDGAT2_c4648(No) (SEQ-ID 34, lane 5 and 6), pDGAT2_c48271(No) (SEQ-ID 102, lane 7 and 8), BnDGAT1 (SEQ-ID 107, lane 9 and 10), AtDGAT1 (SEQ-ID 105, lane 11 and 12), pDGAT2_c699(No) (SEQ-ID 19, lane 13 and 14) and pDGAT2_c2959(No) (SEQ-ID 25, lane 15) encode polypeptides having DGAT activity.

Table 6 summarizes the results of the LPCAT, LPAAT and DGAT activity tests.

TABLE 6 Measured with microsomal protein and [14C]-18:1-LPA, [14C]-18:1-LPC or [14C]-6:0-1,2-DAG. Ofr the in vitro DGAT assay, 1 mg/ml of BSA was added to reduce activity for staying in the linear range. Activity in vitro Activity in SEQ-IDs using vitro using Enzyme (ORF/- 18:3-CoA 22:6-CoA Activity Class Candidate protein/mRNA) nmol/(mg*min) nmol/(mg*min in vivo LPAAT pLPAAT_c6316(No) 13/14/15 81 64 LPCAT pLPAAT_c6316(No) 13/14/15 38 9 DGAT pDGAT2_c699(No) 19/20/21 0.22 0.17 Yes DGAT pDGAT2_c2959(No) 25/26/27 0.95 0.67 Yes DGAT pDGAT2_c4648(No) 34/35/36 1.4 0.17 Yes DGAT pDGAT2_c48271(No) 102/103/104 1.6 0 Yes DGAT pDGAT2-c19425(Ta) 52/53/54 4.0 5.6 Yes DGAT AtDGAT1 105/106/— 1.6 1.2 Yes DGAT BnDGAT1 107/108/— 2.4 1.5 Yes

Example 8: Determination of Substrate Specificity for LPAAT

For determination of substrate specificities of the LPAAT enzymes, clones of the yeast mutant Y13749 (described in example 7) harboring LPAAT genes in the pYES plasmid can be grown at 28° C. in 10 ml selective media (SC-URA) with 2% raffinose as carbon source over night. The next day, expression of the acyltransferase polypeptides can be induced by transferring the cells to fresh media containing 2% galactose, for example by inoculating 100 ml of fresh culture to an optical density (measure at 600 nm) of OD₆₀₀=0.1. Cells are harvested after 24 h incubation at 28° C. by centrifugation at 3000×g for 5 min and resuspended in 1 ml disruption buffer (20 mM Tris/HCL pH 7.6, 10 mM MgCl₂, 1 mM EDTA, 5% glycerol, 0.3 M (NH₄)₂SO₄) and disrupted using acid washed zirconium beads (200 μm average diameter) in a mill (Retsch, Germany) by three minutes agitation at 300 rpm. The supernatant and the beads are transferred to a fresh tube. Disruption buffer is added up to 20 ml and the tube is centrifuged at 8000×g for 5 min. The obtained supernatant is centrifuged for 2 hrs at 42000 rpm at 4° C. The pellet (microsomal fraction) is resuspended in a small volume of 0.1 M phosphate buffer pH 7.2. Protein content in the microsomal fraction is measured according to Bradford (Bradford, M. M. (1976), Anal. Biochem. Bd. 72, pp. 248-254) with bovine serum albumin as standard. Assay mixtures contain 1-5 μg of microsomal protein (the amount is adjusted to achieve linear conditions without substrate limitation), 10 μl of 1 mM [¹⁴C]-18:1-LPA (5000 dpm/nmol), 10 μl of 1 mM acyl-CoA in assay buffer (0.1 M phosphate buffer pH 7.2., 10 mg/ml Bovine Serum Albumine (BSA)) to give a total volume of 100 μl. Like to amount of microsomal protein added to the assay, also the amount of BSA has influence on observed anzmye activities, where higher amounts of BSA result on lower activities and lower amounts of BSA result in higher activities. The enzyme specificity can be tested for different acyl-CoA:s, e.g. 14:0-CoA, 16:0-CoA, 18:1-CoA, 18:2-CoA, 18:3-CoA, γ18:3-CoA, 18:4-CoA, 20:3-CoA, 20:4-CoA, 20:4(n-3)-CoA, 20:5-CoA, 22:5-CoA, 22:6-CoA. Samples are incubated for 4 min at 30° C. The assays are terminated by extraction of the lipids into chloroform according to Bligh and Dyer (Bligh, E. G. and Dyer, W. J. (1959), Can. J. Biochem. Physiol. 37, pp. 911-917). Lipids are separated on thin layer chromatography (TLC) silica 60 plates (Merck) using chloroform/methanol/acetic acid/water (90:15:10:3), and autoradiographic pictures are taken using an instant imager (Packard). The amount of phosphatidic acid (PA) produced in the reaction (and hence the enzyme activity) can be determined from the picture.

Example 9: Determination of Substrate Specificity for LPLAT

For LPCAT and LPEAT activity assay, clones of the yeast mutant Y12431 harboring LPLAT genes in the pYES plasmid can be grown at 28° C. in 10 ml selective media (SC-URA) with 2% raffinose as carbon source over night. The next day, expression of the acyltransferase polypeptides can be induced by transferring the cells to fresh media containing 2% galactose, for example by inoculating 100 ml of fresh culture to an optical density (measure at 600 nm) of OD₆₀₀=0.1 Cells are harvested after 24 h incubation at 28° C. by centrifugation at 3000×g for 5 min and resuspended in 1 ml disruption buffer (20 mM Tris/HCL pH 7.6, 10 mM MgCl₂, 1 mM EDTA, 5% glycerol, 0.3 M (NH₄)₂SO₄) and disrupted using acid washed zirconium beads (200 μm average diameter) in a mill (Retsch, Germany) by three minutes agitation at 300 rpm. The supernatant and the beads are transferred to a fresh tube. Disruption buffer is added up to 20 ml and the tube is centrifuged at 8000×g for 5 min. The obtained supernatant is centrifuged for 2 hrs at 42000 rpm at 4° C. The pellet (microsomal fraction) is resuspended in a small volume of 0.1 M phosphate buffer pH 7.2. Protein content in the microsomal fraction is measured according to Bradford (Bradford, M. M. (1976), Anal. Biochem. Bd. 72, pp. 248-254) with bovine serum albumin as standard. Assay mixtures contain either 10 μl 1 mM [¹⁴C]-18:1-Lysophosphatidlycholine (-LPC), 5000 dpm/nmol (LPCAT assay) or 10 μl 1 mM [¹⁴C]-18:1-Lysophosphatidylethanolamine (-LPE), 5000 dpm/nmol (LPEAT assay), 1-10 μg of microsomal protein (the amount is adjusted to achieve linear conditions without substrate limitation), 10 μl of 1 mM acyl-CoA in assay buffer (0.1 M phosphate buffer pH 7.2., 10 mg/ml BSA) to give a total volume of 100 μl. Like to amount of microsomal protein added to the assay, also the amount of BSA has influence on observed anzmye activities, where higher amounts of BSA result on lower activities and lower amounts of BSA result in higher activities. The enzyme specificity can be tested for different acyl-CoA:s, e.g. 14:0-CoA, 16:0-CoA, 18:1-CoA, 18:2-CoA, 18:3-CoA, γ18:3-CoA, 18:4-CoA, 20:3-CoA, 20:4-CoA, 20:4(n-3)-CoA, 20:5-CoA, 22:5-CoA, 22:6-CoA. Samples are incubated for 4 min at 30° C. The assays are terminated by extraction of the lipids into chloroform according to Bligh and Dyer (Bligh, E. G. and Dyer, W. J. (1959), Can. J. Biochem. Physiol. 37, pp. 911-917). Lipids are separated on thin layer chromatography (TLC) silica 60 plates (Merck) using chloroform/methanol/acetic acid/water (90:15:10:3), and autoradiographic pictures are taken using an instant imager (Packard). The amount of phosphatidyl choline (PC) or phosphatidyl ethanol amine (PE) produced in the reaction (and hence the enzyme activity) can be determined from the picture.

Example 10: Determination of Substrate Specificity for DGAT

For DGAT activity assay, clones of the yeast mutant H1246 harboring either one of pYES-pDGAT2_c699(No), pYES-pDGAT2_c2959(No), pYES-pDGAT2_c4648(No), pYES-pDGAT2_c48271(No), pYES-pDGAT2-c19425(Ta), pYES-AtDGAT1, or pYES-BnDGAT1 can be grown at 28° C. in 10 ml selective media (SC-URA) with 2% raffinose as carbon source over night. The next day, expression of the acyltransferase polypeptides can be induced by transferring the cells to fresh media containing 2% galactose, for example by inoculating 100 ml of fresh culture to an optical density (measure at 600 nm) of OD₆₀₀=0.1. Cells are harvested after 24 h incubation at 28° C. by centrifugation at 3000×g for 5 min and resuspended in 1 ml disruption buffer (20 mM Tris/HCL pH 7.6, 10 mM MgCl₂, 1 mM EDTA, 5% glycerol, 0.3 M (NH₄)₂SO₄) and disrupted using acid washed zirconium beads (200 μm average diameter) in a mill (Retsch, Germany) by three minutes agitation at 300 rpm. The supernatant and the beads are transferred to a fresh tube. Disruption buffer is added up to 20 ml and the tube is centrifuged at 8000×g for 5 min. The obtained supernatant is centrifuged for 2 hrs at 42000 rpm at 4° C. The pellet (microsomal fraction) is resuspended in a small volume of 0.1 M phosphate buffer pH 7.2. Protein content in the microsomal fraction is measured according to Bradford (Bradford, M. M. (1976), Anal. Biochem. Bd. 72, pp. 248-254) with bovine serum albumin as standard. Assay mixtures contain 5 μl 1 mM [¹⁴C]-6:0-DAG, 3000 dpm/nmol, 1-100 μg of microsomal protein (the amount is adjusted to achieve linear conditions without substrate limitation), 5 μl of 1 mM acyl-CoA in assay buffer (50 mM Hepes buffer pH 7.2, 1 mg/ml BSA) to give a total volume of 100 μl. The enzyme specificity can be tested for different acyl-CoA:s, e.g. 14:0-CoA, 16:0-CoA, 18:1-CoA, 18:2-CoA, 18:3-CoA, γ18:3-CoA, 18:4-CoA, 20:3-CoA, 20:4-CoA, 20:4(n-3)-CoA, 20:5-CoA, 22:5-CoA, 22:6-CoA. Samples are incubated for 4 min at 30° C. The assays are terminated by extraction of the lipids into chloroform according to Bligh and Dyer (Bligh, E. G. and Dyer, W. J. (1959), Can. J. Biochem. Physiol. 37, pp. 911-917).Lipids are separated on thin layer chromatography (TLC) silica 60 plates (Merck) using hexane:diethylether:acetic acid (70:30:1), and autoradiographic pictures are taken using an instant imager (Packard). The amount of triacylglycerol (TAG) produced in the reaction (and hence the enzyme activity) can be determined from the picture. In Brassica napus and Arabidopsis, the DGAT involved in TAG-formation in seeds are of the DGAT1 type. The enzyme activity AtDGAT1 and BnDGAT1 for the different substrates can be seen in FIG. 9. The enzyme activity of pDGAT2-c19425(Ta) for the different substrates, compared to AtDGAT1 and BnDGAT1 is shown in FIG. 10. The enzyme activity of pDGAT2_c699(No) and pDGAT2_c4648(No) for the different substrates, compared to AtDGAT1 and BnDGAT1 is shown in FIG. 11. The data in FIGS. 10 and 11 show clearly, that all DGAT2 enzymes shown in these figures vary strongly towards their activities for the various substrates, whereas the DGAT1 involved in TAG formation in Arabidopsis and Brassica napus exhibit less variability towards these different substrates.

Example 11: Determination of Substrate Selectivity for LPAAT

For determination of substrate selectivities of the LPAAT enzymes, clones of the yeast mutant Y13749 (described in example 7) harboring LPAAT genes can be grown at 28° C. in 10 ml selective media (SC-URA) with 2% raffinose as carbon source over night. The next day, expression of the acyltransferase polypeptides can be induced by transferring the cells to fresh media containing 2% galactose, for example by inoculating 100 ml of fresh culture to an optical density (measure at 600 nm) of OD₆₀₀=0.1. Cells are harvested after 24 h incubation at 28° C. by centrifugation at 3000×g for 5 min and resuspended in 1 ml disruption buffer (20 mM Tris/HCL pH 7.6, 10 mM MgCl₂, 1 mM EDTA, 5% glycerol, 0.3 M (NH₄)₂SO₄) and disrupted using acid washed zirconium beads (200 μm average diameter) in a mill (Retsch, Germany) by three minutes agitation at 300 rpm. The supernatant and the beads are transferred to a fresh tube. Disruption buffer is added up to 20 ml and the tube is centrifuged at 8000×g for 5 min. The obtained supernatant is centrifuged for 2 hrs at 42000 rpm at 4° C. The pellet (microsomal fraction) is resuspended in a small volume of 0.1 M phosphate buffer pH 7.2. Protein content in the microsomal fraction is measured according to Bradford (Bradford, M. M. (1976), Anal. Biochem. Bd. 72, pp. 248-254) with bovine serum albumin as standard. The substrate selectivity can be determined by mixing equimolar amounts of different acyl-CoA:s in the same reaction and measure the preference for using the different acyl groups as substrates. The assay is run as in the specificity studies (Example 5) but scaled up 18 times to get sufficient amount of PA for detection. Up to 4 different acyl-CoA:s can be used in the assay in equimolar amount instead of one single acyl-CoA. Samples are incubated for 4 min at 30° C. The assays are terminated by extraction of the lipids into chloroform according to Bligh and Dyer (Bligh, E. G. and Dyer, W. J. (1959), Can. J. Biochem. Physiol. 37, pp. 911-917). Lipids are separated on thin layer chromatography (TLC) silica 60 plates (Merck) using chloroform/methanol/acetic acid/water (90:15:10:3), and autoradiographic pictures are taken using an instant imager (Packard). The phosphatidic acid (PA) is recovered from the plate and the fatty acids methylated in situ on the gel with sulphuric acid (2%) in methanol. Fatty acid methyl esters are extracted with hexane and separated by gas-liquid chromatography (GLC) using a WCOT fused silica 50 m×0.32 mm ID capillary column coated with CP-Wax 58-CB DF=0.3 (Chrompack inc., The Netherlands) and quantified relative to methyl-heptadecanoate added as an internal standard. The selectivity can be determined by calculating the amount of each acyl group that has been acylated to LPA.

Example 12: Determination of Substrate Selectivity for LPLAT

For LPCAT and LPEAT activity assay, clones of the yeast mutant Y12431 harboring LPLAt genes can be grown at 28° C. in 10 ml selective media (SC-URA) with 2% raffinose as carbon source over night. The next day, expression of the acyltransferase polypeptides can be induced by transferring the cells to fresh media containing 2% galactose, for example by inoculating 100 ml of fresh culture to an optical density (measure at 600 nm) of OD₆₀₀=0.1 Cells are harvested after 24 h incubation at 28° C. by centrifugation at 3000×g for 5 min and resuspended in 1 ml disruption buffer (20 mM Tris/HCL pH 7.6, 10 mM MgCl₂, 1 mM EDTA, 5% glycerol, 0.3 M (NH₄)₂SO₄) and disrupted using acid washed zirconium beads (200 μm average diameter) in a mill (Retsch, Germany) by three minutes agitation at 300 rpm. The supernatant and the beads are transferred to a fresh tube. Disruption buffer is added up to 20 ml and the tube is centrifuged at 8000×g for 5 min. The obtained supernatant is centrifuged for 2 hrs at 42000 rpm at 4° C. The pellet (microsomal fraction) is resuspended in a small volume of 0.1 M phosphate buffer pH 7.2. Protein content in the microsomal fraction is measured according to Bradford (Bradford, M. M. (1976), Anal. Biochem. Bd. 72, pp. 248-254) with bovine serum albumin as standard. The substrate selectivity can be determined by mixing equimolar amounts of different acyl-CoA:s in the same reaction and measure the preference for using the different acyl groups as substrates. The assay is run as in the specificity studies (Example 6) but scaled up 18 times to get sufficient amount of PC or PE for detection. Up to 4 different acyl-CoA:s can be used in the assay in equimolar amount instead of one single acyl-CoA. Samples are incubated for 4 min at 30° C. The assays are terminated by extraction of the lipids into chloroform according to Bligh and Dyer (Bligh, E. G. and Dyer, W. J. (1959), Can. J. Biochem. Physiol. 37, pp. 911-917). Lipids are separated on thin layer chromatography (TLC) silica 60 plates (Merck) using chloroform/methanol/acetic acid/water (90:15:10:3), and autoradiographic pictures are taken using an instant imager (Packard). The PC or PE is recovered from the plate and the fatty acids methylated in situ on the gel with sulphuric acid (2%) in methanol. Fatty acid methyl esters are extracted with hexane and separated by gas-liquid chromatography (GLC) using a WCOT fused silica 50 m×0.32 mm ID capillary column coated with CP-Wax 58-CB DF=0.3 (Chrompack inc., The Netherlands) and quantified relative to methyl-heptadecanoate added as an internal standard. The selectivity can be determined by calculating the amount of each acyl group that has been acylated to LPC or LPE.

Example 13: Determination of Substrate Selectivity for DGAT

For DGAT activity assay, clones of the yeast mutant H1246 harboring DGAT genes can be grown at 28° C. in 10 ml selective media (SC-URA) with 2% raffinose as carbon source over night. The next day, expression of the acyltransferase polypeptides can be induced by transferring the cells to fresh media containing 2% galactose, for example by inoculating 100 ml of fresh culture to an optical density (measure at 600 nm) of OD₆₀₀=0.1. Cells are harvested after 24 h incubation at 28° C. by centrifugation at 3000×g for 5 min and resuspended in 1 ml disruption buffer (20 mM Tris/HCL pH 7.6, 10 mM MgCl₂, 1 mM EDTA, 5% glycerol, 0.3 M (NH₄)₂SO₄) and disrupted using acid washed zirconium beads (200 μm average diameter) in a mill (Retsch, Germany) by three minutes agitation at 300 rpm. The supernatant and the beads are transferred to a fresh tube. Disruption buffer is added up to 20 ml and the tube is centrifuged at 8000×g for 5 min. The obtained supernatant is centrifuged for 2 hrs at 42000 rpm at 4° C. The pellet (microsomal fraction) is resuspended in a small volume of 0.1 M phosphate buffer pH 7.2. Protein content in the microsomal fraction is measured according to Bradford (Bradford, M. M. (1976), Anal. Biochem. Bd. 72, pp. 248-254) with bovine serum albumin as standard. The substrate selectivity can be determined by mixing equimolar amounts of different acyl-CoA:s in the same reaction and measure the preference for using the different acyl groups as substrates. The assay is run as in the specificity studies (Example 7) but scaled up 18 times to get sufficient amount of TAG for detection. Up to 4 different acyl-CoA:s can be used in the assay in equimolar amount instead of one single acyl-CoA. Samples are incubated for 4 min at 30° C. The assays are terminated by extraction of the lipids into chloroform according to Bligh and Dyer (Bligh, E. G. and Dyer, W. J. (1959), Can. J. Biochem. Physiol. 37, pp. 911-917). Lipids are separated on thin layer chromatography (TLC) silica 60 plates (Merck) using chloroform/methanol/acetic acid/water (90:15:10:3), and autoradiographic pictures are taken using an instant imager (Packard). The TAG is recovered from the plate and the fatty acids methylated in situ on the gel with sulphuric acid (2%) in methanol. Fatty acid methyl esters are extracted with hexane and separated by gas-liquid chromatography (GLC) using a WCOT fused silica 50 m×0.32 mm ID capillary column coated with CP-Wax 58-CB DF=0.3 (Chrompack inc., The Netherlands) and quantified relative to methyl-heptadecanoate added as an internal standard. The selectivity can be determined by calculating the amount of each acyl group that has been acylated to TAG. 

We claim:
 1. A polynucleotide comprising an expression control sequence operatively linked to a heterologous nucleic acid sequence selected from the group consisting of: a) the nucleic acid sequence of SEQ ID NO: 52 or 54; b) a nucleic acid sequence encoding a diacylglycerol acyltransferase 2 (DGAT2) polypeptide comprising the amino acid sequence of SEQ ID NO: 53; c) a nucleic acid sequence having at least 85% sequence identity to the nucleic acid sequence of SEQ ID NO: 52 or 54 and encoding a DGAT2 polypeptide, wherein said polypeptide has diacylglycerol acyltransferase activity; and d) a nucleic acid sequence encoding a DGAT2 polypeptide having at least 85% sequence identity to the amino acid sequence of SEQ ID NO: 53, wherein said polypeptide has diacylglycerol acyltransferase activity.
 2. The polynucleotide of claim 1, wherein said polynucleotide further comprises a terminator sequence operatively linked to the nucleic acid sequence.
 3. A vector comprising the polynucleotide of claim
 1. 4. A host cell comprising: a) the polynucleotide of claim 1; or b) a vector comprising said polynucleotide; wherein the host cell is a plant cell, a microorganism, or an insect cell.
 5. The host cell of claim 4, wherein the host cell is a plant cell.
 6. The host cell of claim 4, wherein the host cell is yeast, fungus, algae, or moss.
 7. A method for the manufacture of a polypeptide, comprising: a) cultivating the host cell of claim 4 under conditions which allow for the production of said polypeptide; and b) obtaining the polypeptide from said host cell.
 8. A non-human transgenic organism comprising: a) the polynucleotide of claim 1; or b) a vector comprising said polynucleotide, wherein the non-human transgenic organism is a plant or a microorganism.
 9. The non-human transgenic organism of claim 8, wherein the microorganism is a fungus, algae, moss, or yeast.
 10. A method for the manufacture of polyunsaturated fatty acids, comprising: a) cultivating the host cell of claim 4 under conditions which allow for the production of polyunsaturated fatty acids in said host cell; and b) obtaining said polyunsaturated fatty acids from said host cell.
 11. A method for the manufacture of polyunsaturated fatty acids, comprising: a) cultivating the non-human transgenic organism of claim 8 under conditions which allow for the production of polyunsaturated fatty acids in said host cell; and b) obtaining said polyunsaturated fatty acids from said non-human transgenic organism.
 12. The method of claim 11, wherein said polyunsaturated fatty acid is arachidonic acid (ARA), eicosapentaenoic acid (EPA), and/or docosahexaenoic acid (DHA).
 13. A method for the manufacture of an oil, lipid, or fatty acid composition, comprising: a) cultivating the host cell of claim 4 under conditions which allow for the production of polyunsaturated fatty acids in said host cell; b) obtaining said polyunsaturated fatty acids from said host cell; and c) formulating the polyunsaturated fatty acid as an oil, lipid, or fatty acid composition.
 14. The method of claim 13, wherein said oil, lipid, or fatty acid composition is to be used for feed, foodstuffs, cosmetics, or pharmaceuticals.
 15. A method for the manufacture of polyunsaturated fatty acids, comprising: a) cultivating a plant comprising the polynucleotide of claim 1 or a vector comprising said polynucleotide under conditions which allow for the production of polyunsaturated fatty acids in said plant or seeds thereof; and b) obtaining said polyunsaturated fatty acids from said plant or seeds thereof.
 16. The method of claim 15, wherein the polyunsaturated fatty acids are obtained from the seeds of said plant.
 17. A method for the manufacture of an oil, lipid or fatty acid composition, comprising: a) providing a polyunsaturated fatty acid produced by the method of claim 15; and b) formulating said polyunsaturated fatty acid as an oil, lipid or fatty acid composition.
 18. A method for the manufacture of an oil, lipid or tatty acid composition, comprising: a) cultivating a plant comprising the polynucleotide of claim 1 or a vector comprising said polynucleotide under conditions which allow for the production of polyunsaturated fatty acids in said plant or seeds thereof; and b) obtaining an oil, lipid or fatty acid composition from said plant or seeds thereof.
 19. The method of claim 18, wherein the oil, lipid or fatty acid composition is obtained from the seeds of said plant.
 20. A method for the production of feed, foodstuffs, cosmetics or pharmaceuticals, comprising: a) obtaining an oil, lipid or fatty acid composition produced by the method of claim 18; and b) processing said oil, lipid or fatty acid composition to produce feed, foodstuffs, cosmetics or pharmaceuticals.
 21. A method for the manufacture of polyunsaturated fatty acids, comprising: a) obtaining an oil, lipid or fatty acid composition produced by the method of claim 18; and b) obtaining polyunsaturated fatty acids from said oil, lipid or fatty acid composition.
 22. A plant, or a plant part, plant cell, or seed thereof, wherein said plant, or said plant part, plant cell, or seed thereof comprises: a) the polynucleotide of claim 1; or b) a vector comprising said polynucleotide.
 23. The polynucleotide of claim 1, wherein said heterologous nucleic acid sequence encodes a DGAT2 polypeptide having diacylglycerol acyltransferase activity and has at least 90% sequence identity to the amino acid sequence of SEQ ID NO:
 53. 24. The polynucleotide of claim 1, wherein said heterologous nucleic acid sequence encodes a polypeptide having diacylglycerol acyltransferase activity and has at least 95% sequence identity to the amino acid sequence of SEQ ID NO:
 53. 